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Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and it is
characterized by progressive impairment in multiple cognitive domains of sufﬁcient sever-
ity to interfere with individuals’ daily living activities. Historically, the diagnosis of AD has
been based on the identiﬁcation of a clinical syndrome, and accuracy studies of the current
clinical criteria conducted in referral clinics have shown high sensitivity for AD. However,
the identiﬁcation of the disease is still not perfect, and there is growing evidence that the
use of biomarkers will increase our ability to better indentify the underlying biology of AD,
especially in its early stages.These biomarkers will improve the detection of the patients
suitable for research studies and drug trials, and they will contribute to a better manage-
ment of the disease in the clinical practice. In this review, we discuss the most studied
biomarkers in AD: cerebrospinal ﬂuid proteins, structural magnetic resonance imaging,
functional neuroimaging techniques, and amyloid imaging.
Keywords: Alzheimer’s disease, mild cognitive impairment, biomarker, cerebrospinal ﬂuid, magnetic resonance
imaging, positron emission tomography
INTRODUCTION
Alzheimer’s disease (AD) is the most frequent neurodegenerative
disease (Ferri et al., 2005) and is characterized by a progressive
dementia that occurs in middle or late life. The neuropathological
hallmark of AD is the presence of cortical intracellular neuroﬁb-
rillary tangles (NFT) and extracellular β-amyloid (Aβ) plaques
(Braak and Braak, 1991), which leads to synapse dysfunction,
neuronal cell loss and subsequent brain atrophy (Ballard et al.,
2011). In the past few decades the knowledge of the key path-
ogenic mechanisms of the disease has improved, but they are
still not completely understood (Querfurth and LaFerla, 2010).
The natural history of AD could be divided in three different
phases: the pre-clinical phase, where the pathogenic mechanisms
of the disease have started but no symptoms can be identiﬁed;
the prodromal phase, where mild cognitive symptoms appear,
but there are not severe enough to meet dementia criteria; and
the dementia phase (Dubois et al., 2007). On the other hand,
mild cognitive impairment (MCI) is a clinical construct cre-
ated to capture patients with subtle cognitive symptoms at risk
for AD (Petersen et al., 2009). However, some subjects develop
other types of dementias, do not progress, or even revert to nor-
mal cognition (Ganguli et al., 2004; Brooks and Loewenstein,
2010). Therefore, it is difﬁcult to label MCI patients as having
prodromal AD.
Currently, the most frequently used clinical diagnostic crite-
ria for AD are the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR; APA, 2000) and the National Institute
of Neurological Disorders and Stroke-Alzheimer Disease and
Related Disorders (NINCDS–ADRDA; McKhann et al., 1984)
working group. These criteria are fulﬁlled in a two-step diag-
nostic process. First, the dementia syndrome is established and
then, criteria based on the clinical features of the AD type
dementia are applied. The DSM-IV-TR criteria require the pres-
ence of impairment in multiple cognitive domains of sufﬁ-
cient severity to interfere with the individuals’ activities of daily
living to diagnose dementia. Hence, the clinical diagnosis of
AD is not possible until a patient reach the dementia phase
of the disease. On the other hand, these criteria have shown
to have good sensitivity and speciﬁcity to distinguish between
patients with AD type dementia and non-demented subjects, but
are less accurate to differentiate AD dementia from other pri-
mary dementias (Knopman et al., 2001; Ballard et al., 2011).
In fact, up to 20% of patients clinically diagnosed with AD
do not have AD pathology at autopsy (Mayeux et al., 1998;
Lim et al.,1999).
A more accurate and earlier diagnosis of AD (e.g., in MCI
patients that will progress to the AD dementia phase or ideally
those subjects in the pre-clinical phase) could enable the admin-
istration of potential disease-modifying drugs that would have a
great impact on patients’ life and profound implications for pub-
lic health (Brookmeyer et al., 1998). In this context, there is a
need of speciﬁc biological markers forAD diagnosis in the earliest
stages.Abiomarkerisdeﬁnedasameasureablefeaturethatcanbe
used to diagnose a physiologic or pathologic condition. The ideal
biomarkerofADwouldbe:(1)directedatthefundamentalpatho-
physiology of the disease, (2) a marker of the presence of disease
itself, (3) efﬁcacious at prodromal, and even pre-clinical stages of
AD,(4)anindicatorof disease’sseverity,(5)amarkerof treatment
effectiveness,and(6)inexpensiveandnon-invasive(Klunk,1998).
In the case of AD,different biomarkers have been described using
diverseapproaches.Thedevelopmentof cerebrospinalﬂuid(CSF)
assaysandneuroimagingtechniquesthatcanprovideinformation
about the presence of AD pathological changes has been a major
step forward in the ﬁeld. Consequently, biomarkers for AD are
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(NIA–AA) workgroup to include the experience in research over
the past 25years (McKhann et al.,2011). The NIA–AA proposed a
series of diagnostic classiﬁcation from pre-clinical AD to MCI to
full-blownAD,andintroducedCSFandneuroimagingbiomarkers
as supportive features of the disease (Albert et al.,2011;McKhann
et al.,2011; Sperling et al.,2011). However,the authors cautioned
about the use of biomarkers, and stated that their use should be
limited to research and drug trials. Nevertheless, the core clinical
criteria for AD remained relatively intact in the new criteria.
Thisreviewwillfocusonthemostwidelystudiedandcurrently
accepted sources of biomarkers in AD: CSF, magnetic resonance




markers of neurodegenerative diseases. Typically, the CSF bet-
ter reﬂects the brain neurochemistry, while biochemical values
in plasma or serum may be affected by many non-neurological
factors. CSF biomarker research has focused mainly on molecules
related to the central neuropathological features of AD, such as
Aβ,themaincomponentof thesenileneuriticplaques(SNP),and
tau proteins that are part of the NFTs. Aβ is a 36–43 amino acid
peptideoriginatedfromproteolysisof theamyloidproteinprecur-
sor (Querfurth and LaFerla,2010). SNPs are mainly composed by
Aβ protein with 40 (Aβ40)o r4 2( A β42) amino acids, and it seems
that Aβ deposition begins with Aβ42, and during plaque matura-
tion, they acquire Aβ40 (Iwatsubo et al., 1994). By contrast, NFTs
are formed by tau proteins, a microtubule-associated stabilizing
protein essential for axonal transport. Tau is hyperphosphory-
lated in AD, which tends to aggregate, leading to synaptic and
neuronal dysfunction (Lee, 1996; Blennow et al., 2010; Querfurth
and LaFerla, 2010). This process of NFTs formation starts in the
entorhinal cortex, spreading to the hippocampus, and then to the
rest of the brain. These neuropathological changes begin early,
even decades before the onset of clinical symptoms of dementia
(Braak and Braak, 1991), but the relative contributions of altered
tau and amyloid metabolism to neurodegeneration remain under
investigation. Nevertheless,NFTs are more robust associated with
measures of synapse loss and cognitive impairment that SNPs
(Gomez-Isla et al.,1997).
Typically,ADpatientshavelowerlevelsofAβ42 intheCSFcom-
pared to normal controls,Aβ40 tends to remain constant, and tau
(t-tau) and phosphorylated tau (p-tau) increase (Arai et al.,1995;
Blennow et al., 1995; Motter et al., 1995; Vigo-Pelfrey et al., 1995;
Galasko et al., 1998; Kurz et al., 1998; Shoji et al., 1998; Hulstaert
et al., 1999; Andreasen et al., 2001; Sunderland et al., 2003; Lew-
czuk et al., 2004; Schoonenboom et al., 2004; Shaw et al., 2009).
The low CSF Aβ42 levels in this entity may represent the reten-
tion of the peptide into plaques, resulting in reduced availability
to diffuse into the CSF. This is supported by the ﬁndings that
Aβ42 intheCSFisinverselycorrelatedwithamyloidplaqueloadat
autopsy (Strozyk et al.,2003;Tapiola et al.,2009) and as measured
FIGURE 1 | Mean CSF total tau levels in autopsied proven cases.




AD patients may stem from release into CSF during neurodegen-
eration (Blennow et al., 1995), although the exact mechanism is
not known. T-tau and p-tau concentrations in the CSF have been
associatedwithNFTloadatautopsy(Buergeretal.,2006a;Tapiola
et al., 2009), as well as with cognitive decline and brain atrophy
(Buerger et al.,2002; Hampel et al.,2005; Fjell et al.,2010;Vemuri
et al.,2010b).
Low CSF Aβ42 and high t-tau or p-tau proteins have shown
high accuracy for AD diagnosis (Galasko et al., 1998; Andreasen
et al., 2001; Schoonenboom et al., 2004). Studies that compared
AD patients with normal control subjects have demonstrated that
low Aβ42 had 78–100% sensitivity and 47–81% speciﬁcity for AD
diagnosis; high CSF t-tau levels had 70% sensitivity and 92%
speciﬁcity and p-tau showed 77% sensitivity and 87% speciﬁcity.
However, p-tau appears to be better than t-tau in the diagnosis
of AD, and it has shown a positive predictive value of 90%, espe-
cially p-tau phosphorylated at threonine 181 (p-tau181; Hampel
et al., 2004a; Mitchell, 2009). Figure 1 shows the t-tau levels in
AD, frontotemporal dementia (FTD), and normal autopsied sub-
jects, and Figure 2 shows the Aβ42 levels in the same population
(Schoonenboom et al., 2004).
BecausesomestudiesfoundthatAβ42 andtaulevelsalonewere
not sufﬁcient to differentiate AD from normal controls or other
dementias, the Aβ42/tau ratio is used to improve the diagnosis of
AD. A meta-analysis showed that the Aβ42/tau ratio had a sen-
sitivity of 71% and speciﬁcity of 83% for AD (Hampel et al.,
2004b); and a recent study showed that the “signature” of AD,
based on the CSF Aβ42/p-tau181 ratio cutoffs, was present in 90%
of the AD patients compared to 36% in the normal control group
(De Meyer et al., 2010). Although, these CSF biomarkers seem
to be useful to diagnose AD, they are not sensitive enough to
assess disease progression (Sunderland et al., 1999; Vemuri et al.,
2010b). Nevertheless, higher CSF t-tau and lower Aβ42 values
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FIGURE 2 | Mean CSFAβ42 levels in autopsied proven cases. Extracted
from Schoonenboom et al. (2004). AD, Alzheimer’s disease; FTD,
frontotemporal dementia.
have been associated with rapid cognitive decline, no response
to cholinesterase inhibitor treatment and a higher mortality in
patients with AD dementia (Wallin et al.,2010).
Cerebrospinal ﬂuid biomarkers might have a role in the differ-
ential diagnosis of AD and other dementias. Patients with demen-
tia with Lewy bodies (DLB), like AD patients, have lower levels of
Aβ42 intheCSFcomparedtonormalcontrols,reﬂectingthatmost
of these subjects also present AD pathology. Nevertheless, shorter
amyloid peptides (Aβ37,A β38, and Aβ40) appear to be slightly
more elevated in AD dementia (Bibl et al., 2006). Consequently,
theAβ42/Aβ37 andAβ42/Aβ38 ratiosseemedtobetterdiscriminate
AD from DLB (Bibl et al., 2006; Mulugeta et al., 2010). T-tau and
p-tau levels are normal or high in DLB, but most studies have
shown that these markers’ levels in DLB are deﬁnitely lower than
those found in AD. Other proposed biomarker for the differenti-
ation of AD from DLB was monomeric soluble α-synuclein, but
the available studies in DLB patients showed conﬂicting results.
Elevated, unchanged and decreased total α-synuclein levels have
been reported in these patients compared to AD and control sub-
jects (Mukaetova-Ladinska et al., 2010). In addition, there are
limited data about oligomeric α-synuclein in CSF, although it
couldbepotentialbiomarkerforsynucleinopathies(Tokudaetal.,
2010). Possibly, the combination of all these markers will help to
distinguish between AD and DLB in the future.
In FTD, CSF Aβ42 levels are lower than in control subjects but
higher than in AD, while t-tau and p-tau levels are higher than
in controls but lower that in AD patients (Hulstaert et al., 1999;
Riemenschneider et al., 2002). Hence, t-tau/Aβ42 and p-tau/Aβ42
ratios could be a useful tool to distinguish AD from FTD (Bian
et al., 2008; Cruz de Souza et al., 2011). Creutzfeldt–Jakob disease
(CJD) is characterized by decreased CSF Aβ42 concentrations and
veryhight-taulevels,reﬂectingintenseneuronaldamage,whilep-
tau levels are normal (Kapaki et al., 2001; Riemenschneider et al.,
2003; Buerger et al.,2006b). Current data suggest that p-tau levels
could be the most relevant marker to differentiate AD from other
types of dementias (Hampel et al., 2004b; Kapaki et al., 2007;
Koopman et al., 2009).
Cerebrospinalﬂuidbiomarkersmayalsobeusefulinpredicting
progression to AD in subjects with MCI (Andreasen et al., 1999;
Hampel et al., 2004c; Ewers et al., 2007; Brys et al., 2009). Low
CSFAβ42 levels predicted conversion with 60–80% sensitivity and
65–100% speciﬁcity,while t-tau levels had 83–86% sensitivity and
56–90%speciﬁcity,andp-tauhad73–84%sensitivityand47–88%
speciﬁcity (Hampel et al.,2004b). However,the conversion to AD
dementiainMCIsubjectshasshownsigniﬁcantvariabilityamong
different CSF studies. Hansson et al. (2006) found high sensitivity
(95%) and speciﬁcity (87%) for the conversion from MCI to AD
dementia using a combination of t-tau and Aβ42/p-tau181 ratio
cutoff values. By contrast, a multicenter CSF study found lower
sensitivity (83%) and speciﬁcity (72%) for the conversion from
MCI to AD than single-site studies, with a considerable inter-site
assay variability that highlights a need for standardization of ana-
lytical techniques and subject selection (Mattsson et al., 2009).
Other large multicenter studies have conﬁrmed the high predic-
tive value of these CSF biomarkers in the identiﬁcation of cases
with prodromal AD in the context of the MCI syndrome (Shaw
et al.,2009;Visser et al., 2009).
The CSF biomarkers have been used to identify the pre-clinical
stage of AD. Cross-sectional studies in normal control individu-
als carrying the ApoE4 allele showed lower CSF Aβ42 and higher
p-tau181 levels (Peskind et al.,2006; Kester et al.,2009; Shaw et al.,
2009;Vemurietal.,2010a).Interestingly,CSFlevelsof Aβ42 corre-
latedwithbrainvolumeinthisgroupofsubjects,whileinMCIand
AD dementia patients, whole-brain volume correlated with CSF
t-tau and p-tau181 (Fagan et al., 2009). A longitudinal CSF study
in normal controls found increased t-tau levels and no change
in Aβ42 after a 1-year follow-up (Vemuri et al., 2010b). A few
longitudinal studies have assessed which CSF biomarker or com-
bination of biomarkers better predict AD dementia or cognitive
decline.Faganetal.(2007)demonstratedthatCSFtau/Aβ42 ratios
may predict future dementia in cognitively normal older subjects
and two other studies showed that low levels of CSF Aβ42 pre-
dicted cognitive decline, as measured with the mini mental status
examination(MMSE;Gustafsonetal.,2007;Stomrudetal.,2007).
Although there are studies that showed that CSF Aβ42 could pre-
dict prodromal AD, there was a wide SD in these subjects, which
made difﬁcult to determine individually who will progress to AD.
Further studies are needed to assess changes in CSF markers over
time and to determine the best CSF markers of change.
STRUCTURAL NEUROIMAGING MARKERS
Structuralneuroimagingtechniquesarenormallyperformeddur-
ing the clinical assessment of patients with dementia, mainly to
rule out structural lesions, such as brain tumors, normal pressure
hydrocephalus, or vascular lesions. The MRI has shown high sen-
sitivity to detect brain atrophy caused by the neurodegenerative
process (Bobinski et al., 2000). Several methods are used to ana-
lyze MRI data including visual inspection, volumetry, or region
of interest (ROI) analysis (applying manual tracing, automated,
or semi-automated techniques) and voxel based morphometry
(VBM; Vemuri and Jack, 2010). There are beneﬁts and limi-
tations of these methods. The visual rating of the images and
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ROI analysis depend on the a priori choice of structures, while
VBM is a whole-brain operator-independent analysis (Ashburner
and Friston, 2000). However, VBM analysis only allows compar-
ing groups of patients, and it is not useful to classify individual
cases. Visual assessment of MRI scans is a fast method to assess
brain atrophy but is not the most precise (Raji et al., 2010).
Volumetry of the medial temporal lobe structures is the most
common quantitative method used in AD. The traditional man-
ual tracing is time-consuming, and consequently, automated or
semi-automatedmethodsthatrequirenosigniﬁcantmanualinter-
ventionhavebeendeveloped.Othermethodstoanalyzesequential
MRIs are boundary shift integral (BSI) and tensor-based mor-




Brain MRI studies have shown that AD patients have a wide-
spread cortical volume loss, including the frontal lobes, the tem-
poroparietal regions, precuneus, and mesial temporal lobes, with
relative sparing of the sensorimotor,visual,and cerebellar regions
(Du et al., 2001; Good et al., 2001; Thompson et al., 2001; Karas
etal.,2003;Testaetal.,2004;Ishiietal.,2005;Dickersonetal.,2008;
Burtonetal.,2009).Longitudinalstudieshavesuggestedthatatro-
phy stars in the medial temporal lobes and fusiform gyrus in the
prodromal phase of the disease, then spreads out to the posterior
temporalandparietallobes,andbythetimeofthedementiaphase,
it involves the medial temporal lobes,temporoparietal cortex,and
thefrontallobe(Whitwelletal.,2007).Thispatternofatrophypro-
gression on MRI appears to follow the distribution of NFT in the
different Braak and Braak (1991) pathological stages (Whitwell
et al., 2008). In AD, there is also a greater rate of brain atrophy
over time compared with healthy elderly subjects (1.9–2.2% per
year versus 0.5–0.7% per year; O’Brien et al., 2001; Sluimer et al.,
2008a,b; Henneman et al., 2009). Hippocampal and whole-brain
atrophy in AD correlated well with cognitive performance and
measures of disease severity (Jack et al., 2008a; Ridha et al., 2008;
Schott et al.,2008).
In amnestic MCI subjects as a group, MRI studies show a sim-
ilar pattern of brain atrophy to that observed in AD (Jack et al.,
2000; Chetelat et al., 2002; Karas et al., 2004; Bell-McGinty et al.,
2005; Whitwell et al., 2008) and rates of whole-brain atrophy
are around 1% per year, between AD and control subjects (Jack
et al., 2004). Whole-brain atrophy rate in MCI is associated with
impaired cognitive performance (Evans et al., 2010) and predicts
progression to AD dementia (Spulber et al., 2008). Whole-brain
techniqueshavealsoshownthathigherratesof atrophyinspeciﬁc
areas such as the hippocampus, posterior cingulated gyrus, and
superior parietal cortex were associated with incident AD in MCI
cases (Chetelat et al.,2005),and hippocampal and basal forebrain
volumes in normal subjects predicted future development of AD
(Halletal.,2008).Interestingly,arecentstudyshowedthatnormal
subjectswiththeADCSFproﬁlehadincreasedratesof brainatro-
phy over time, suggesting they may be in the pre-clinical phase of
the neurodegenerative process (Schott et al., 2010). Nevertheless,
thisobservationrequiresalongerfollow-upperiodtodemonstrate
that this particular group of subjects has a higher risk to develop
AD dementia.
Because the most important clinical manifestation of AD is
memory loss, the majority of the researchers have focused on the
studyof hippocampalatrophyasamarkerof thedisease.Different
neuroimaging studies assessing the mesial temporal lobe struc-
tures have consistently shown smaller hippocampal volumes in
AD patients compared to controls (Pennanen et al., 2004). Mea-
sures of hippocampal atrophy correlate well with the degree of
cognitive impairment (Jack et al., 2000; Mortimer et al., 2004)
and with AD pathology and hippocampal sclerosis in MRI-post-
mortem studies (Jagust et al., 2008). Both normal aging and AD
have gradual volume loss overtime, but as with whole-brain vol-
ume is greater in AD; the annual rate of hippocampal atrophy




2007; Teipel et al., 2007). A recent meta-analysis showed that this
measure could identify MCI converters with a sensitivity of 73%
and a speciﬁcity of 81% (Yuan et al., 2009). Although decreased
entorhinal cortical thickness has been proposed as a predictor of
conversion from MCI to AD, measures of decrease hippocampal
volume appeared to be a more robust predictor.
There are several limitations for the use of whole-brain or hip-
pocampal volume as a sole biomarker for AD. One of the most
important is that small brain volumes can also be seen in normal
aging, and consequently, is difﬁcult to separate cases with early
AD from normal controls. On the other hand, the rate of change
on whole-brain,entorhinal,and hippocampal volumes seemed to
be good markers of neurodegeneration and they can be useful in
determining the effects of AD therapies, but these techniques are
labor intensive and limited to research studies.
FUNCTIONAL NEUROIMAGING MARKERS
Brain functional neuroimaging techniques – positron emission
tomography(PET)andsinglephotonemissioncomputedtomog-
raphy (SPECT) – allow a broad range of cerebral functions to be
assessed in patients currently living with dementia.Actually,brain
metabolism, brain perfusion, and different neurotransmitter sys-
tems can be measured with a great variety of PET and SPECT
tracers. However, brain metabolism with the glucose analog 2-
[18F]-ﬂuoro-2-deoxy-d-glucose (18F-FDG) and brain perfusion
with technetium-99m hexamethylpropylamine oxime (99mTc-
HMPAO) are the two more widely employed techniques in the
evaluation of patients with dementia,both in clinical practice and
in research. Brain SPECT with 99mTc-HMPAO studies provide
informationof theregionalcerebralbloodﬂow,and 18F-FDGPET
estimates the regional brain rate of glucose consumption, there-
fore providing information about the pattern of neuronal loss or
synapse dysfunction in patients with dementia.
The pattern of SPECT hypoperfusion and PET hypometab-
olism usually seen AD involves the anterior medial temporal
lobes, the posterior cingulate and posterior temporoparietal cor-
tex (Kogure et al., 2000; Ishii et al., 2001; Alexander et al., 2002;
Bradley et al., 2002). Nevertheless, SPECT seems to be less accu-
rate than PET for the diagnosis of AD. One autopsy study found
that this technique alone had a sensitivity of 63% and a speciﬁcity
of 93% to diagnose AD (Jagust et al., 2001). On the other hand,
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SPECTseemedtobeusefuldifferentiatingADfromotherdemen-
tias.ThesensitivityofthisprocedurediscriminatingADfromFTD
was 71.5% and the speciﬁcity was 78.2%, while its sensitivity and
speciﬁcity to differentiate AD from vascular dementia were 71.3
and 75.9%, respectively (Dougall et al., 2004). In MCI patients,
SPECT has shown that can predict conversion to AD with a test
accuracy of 82% (Huang et al.,2007).
Positron emission tomography studies in earlyAD have shown
a pattern of reduced metabolism in the posterior cingulate
(Minoshima et al., 1997) and mesial temporal cortices. As the
diseaseprogresses,thereisagreaterinvolvementoftheparietotem-
poral and frontal cortices (Ishii et al.,2001; Silverman et al.,2001;
Alexander et al., 2002; Drzezga et al., 2003). This progression of
the areas of hypometabolism correlated with cognitive deteriora-
tion over time as measured by neuropsychological tests (Engler
et al., 2006; Kadir et al., 2010) and dementia severity scales (Fos-
ter et al., 1984; Minoshima et al., 1995; Silverman et al., 2001;
Mosconi et al., 2005). A meta-analysis showed that pooled 18F-
FDG PET sensitivity and speciﬁcity to differentiate AD patients
from normal subjects were 86% in both cases, but the variability
was important between the studies (sensitivity from 61 to 100%
and speciﬁcity from 54 to 100%; Patwardhan et al., 2004). PET
also seems to be a good tool to differentiate AD from other forms
of dementia.Inanautopsyconﬁrmedstudy,thepresenceof occip-
ital hypometabolism was able to distinguish DLB from AD with
90%sensitivityand80%speciﬁcity(Minoshimaetal.,2001).This
technique also has a high speciﬁcity and sensibility to differentiate
AD and FTD (Koeppe et al., 2005; Foster et al., 2007; Panegyres
et al.,2009).
18F-FDGPETappearstobeapromisinginstrumenttodiscrim-
inate those patients with MCI who will progress to AD dementia.
These patients show a medial temporal and posterior cingulate
corticeshypometabolismcomparedwithhealthycontrols(Chete-
lat et al., 2003; Anchisi et al., 2005; Drzezga et al., 2005). A recent
meta-analysis has also shown that 18F-FDG PET performs slightly
better than SPECT and structural MRI in identifying the pro-
dromal phase of AD in patients with a clinical diagnosis of MCI
(pooled sensitivity of 89% and speciﬁcity of 85%; Yuan et al.,
2009). Interestingly, similar metabolic reductions in the same
regions as those found in MCI and AD patients have been seen
in asymptomatic subjects at risk of AD, i.e., in persons with sub-
jective memory complains (Caselli et al., 2008), carriers of an
apolipoproteinEε4(ApoE4)allele(Reimanetal.,1996,2001,2004,
2005),with abnormalities in the CSF markers (Petrie et al.,2009),
or with a maternal history of AD (Mosconi et al., 2007, 2009).
Furthermore,hippocampalhypometabolismduringnormalaging
predictedcognitivedeclineyearsinadvanceof theclinicaldiagno-




the PET AD pattern has been incorporated into the new clinical
criteria for prodromal AD (Dubois et al., 2007), pre-clinical AD
(Sperling et al.,2011), and MCI due to AD (Albert et al.,2011).
MOLECULAR NEUROIMAGING MARKERS
The development of PET radiotracers that bind to brain amy-
loid has revolutionized the use of neuroimaging techniques in
patients with dementia. These molecules allow the localization
of AD pathology in vivo, and have helped to further our under-
standing of the underlying biology of AD. The most actively
tested tracers are N-methyl-[11C]2-(4 -methylaminophenyl)-6-
hydroxybenzothiazole (11C-PIB; Klunk et al., 2003), (E)-4-(2-(6-
(2-(2-(2-(18)F-ﬂuoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-
methyl benzenamine (18F-AV-45; Choi et al., 2009) and 2-(1-96-
(2-18F-ﬂuoroethyl)(methyl)amino)-2-naphthyl)ethyldene) mal-
ono nitrile (18F-FDDNP; Small et al., 2006; Shin et al., 2008),
but there are multiple 11C and 18F compounds under investiga-
tion such as trans-4-(N-methyl-amino)-4 -2-[2-(2-[18F]ﬂuoro-
ethoxy)-ethoxy]-ethoxy-stilbene (18F-BAY94-9172; Rowe et al.,
2008), 4-N-[11C-methyl]amino-4 -hydroxystilbene (11C-SB-13;
Verhoeff et al., 2004) and 2-(2-[2-dimethylaminothiazol-5-
yl]ethenyl)-6-(2-[ﬂuoro]ethoxy)benzoxazole (11C-BF-227; Kudo
et al., 2007). While 11C have better afﬁnity for ﬁbrillar amyloid
than 18F compounds,the former have a very short life,which lim-
its its use to centers with an available cyclotron that can produce
them. Among these tracers, 11C-PIB is the most widely used and
bestcharacterized.Thisthioﬂavin-TderivedbindsﬁbrillarAβwith
high afﬁnity and its brain retention correlates well with levels of
amyloid inAD brain tissue (Mathis et al.,2002,2003; Klunk et al.,
2004; Ikonomovic et al.,2008; Leinonen et al., 2008).
Positron emission tomography studies with 11C-PIB have
demonstrated an increased retention of this tracer in frontal and
parietotemporalcortices,aswellasinthestriatumofalmostallAD
patients compared with controls (Klunk et al., 2004; Edison et al.,
2006; Rowe et al., 2007). However, it is important to note that a
positive 11C-PIB PET scan can also be seen in other entities,often
misdiagnosedasAD,suchasDLBandcerebralamyloidangiopathy
(Edison et al., 2008; Gomperts et al., 2008; Dierksen et al., 2010).
11C-PIBretentioninADcorrelateswithratesof whole-brainatro-
phy (Archer et al., 2006), parietotemporal hypometabolism on
18F-FDG PET (Klunk et al.,2004; Edison et al.,2006; Engler et al.,
2006), and decreased CSF Aβ42 levels (Fagan et al., 2006; Grim-
mer et al., 2009; Jagust et al., 2009). There are few longitudinal
studies using amyloid ligands, and the observation time has been
relatively short, because these techniques have only been avail-
able for research since 2004. Recent longitudinal studies in AD
patients assessing amyloid load and progression of neurodegener-
ation using structural MRI or 18F-FDG PET found that 11C-PIB
retention was relatively stable over time, while neurodegenerative
markers worsen in parallel with cognitive decline (Engler et al.,
2006; Jack et al., 2009; Scheinin et al., 2009; Kadir et al., 2010).
These ﬁndings are consistent with the hypothesis that there is
dissociationbetweentheamyloiddepositionandtheneurodegen-
erative process,where amyloid accumulation precedes the clinical
symptoms and reaches its maximum detectable level before the
cognitivedeﬁcitsareevident(Jacketal.,2010a).However,another
recent study has shown increases of 11C-PIB retention in mild to
moderate AD dementia, questioning this hypothesis and suggest-
ing that Aβ deposition might slow down in the later stages of the
disease, but it is still present (Villemagne et al.,2011).
In MCI patients, 11C-PIB PET shows a bimodal distribution
with some subjects having a pattern of retention similar to AD
patients and others similar to control subjects (Pike et al., 2007;
Rowe et al., 2007; Jack et al., 2009; Wolk et al., 2009). In these
patients,theAβburdenisrelatedtoepisodicmemoryimpairment
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butnottoothercognitivetasks(Pikeetal.,2007).ThePIB-positive
MCI subjects are more likely to carry an ApoE4 allele and to
progress to AD (Pike et al., 2007; Forsberg et al., 2008; Okello
et al.,2009;Wolk et al.,2009; Jack et al.,2010b). Factors that seem
to inﬂuence a shorter time to progression in PIB-positive subjects
is the presence of hippocampal atrophy, higher 11C-PIB reten-
tion values and having an ApoE4 allele (Okello et al., 2009; Jack
etal.,2010b;Koivunenetal.,2011).Longitudinalstudiesassessing
changes in 11C-PIB retention in MCI patients are contradictory.
Jack et al. (2009) rescanned MCI subjects after a single year, but
only a minimal change has seen in this group of persons. How-
ever, Villemagne et al. (2011) have shown small but signiﬁcant
increases in 11C-PIB cortical retention in MCI patients from the
baseline studies to scans to those performed from 20months to
3years later; other studies have reported similar results (Kadir
et al.,2010; Koivunen et al., 2011).
In agreement with autopsy data (Price and Morris, 1999),
approximately20–30%ofelderlycognitivelynormalsubjectsshow
somedegreeof 11C-PIBretention,mainlyintheprefrontalcortex,
posterior cingulate and precuneus regions (Mintun et al., 2006;
Pike et al., 2007; Rowe et al., 2007; Aizenstein et al., 2008). In
fact, the proportion of 11C-PIB-positive healthy control subjects
increases with age (Morris et al., 2010). In these subjects, some
studies have reported a strong relationship between impaired
episodic memory performance and 11C-PIB binding that could
be modiﬁed by cognitive reserve (Pike et al., 2007; Mormino
et al., 2009; Rentz et al., 2010), but some others have not found
this association (Mintun et al., 2006; Jack et al., 2008b; Stornadt
et al., 2009). Studies directly relating structural MRI data to Aβ
burden in control subjects has yield contradictory results. Some
authors have reported reduced hippocampal volume (Mormino
et al., 2009; Stornadt et al., 2009), a cortical thinning pattern con-
sistent with early AD (Dickerson et al., 2008; Becker et al., 2010)
andanincreasedrateofbrainatrophy(Scheininetal.,2009),while
others have found brain atrophy only in 11C-PIB-positivesubjects
or in normal individuals with subjective cognitive impairment




toAD was increased almost ﬁve-fold with a 11C-PIB-positive PET
scan.Villemagneetal.(2011)performedserial 11C-PIBPETscans
in a group of normal subjects and found that 25% of individuals
with a positive scan developed MCI orAD dementia by 3years. In
addition, the authors also reported an increase in 11C-PIB brain
retention in those control subjects with a positive baseline scan,
suggesting a slow process of Aβ accumulation in the brain over
time (Villemagne et al., 2011). These data are consistent with
the hypothesis that amyloid imaging can detect Aβ accumula-
tion in advance of the onset of dementia (Jack et al., 2010a),
although more longitudinal studies are required to determinate
the sequence of pathological events in the process from normalcy
toAD.Figure3showsthespectrumof amyloiddepositioninnor-
mal controls, MCI and AD cases, as measured with 11C-PIB PET
(Mathis et al.,2007).
Although amyloid imaging is a relatively new technique, we
can state that it accurately detects Aβ accumulation in the brain.
FIGURE 3 |Transaxial and sagittal planes of
11C-PIB PET scans in a




11C-PIB-positive MCI subject (MCI+), a highly
11C-PIB-positive MCI subject (MCI++), and a
11C-PIB-positiveAD
patient (AD). Reprinted from Mathis et al. (2007).
However,it has been reported the case of a patient clinically diag-
nosed of mild AD with a negative 11C-PIB PET scan, where low
levels of amyloid pathology at autopsy were found (Cairns et al.,
2009). On the other hand,there are not reported cases of subjects
with a positive amyloid PET without presence of Aβ at autopsy.
These data suggests that 11C-PIB PET is a technique with high
speciﬁcity and positive predictive value for early AD diagnosis.
Nevertheless, having an 11C-PIB-positive scan does not mean to
be at a pre-dementia stage of AD, and the prognostic value of
increased Aβ load on PET has to be established with more exten-
sive longitudinal studies. In this scenario, adding techniques that
assess functional brain changes suggesting early AD could be of
special interest. Deﬁnitely, the information obtained with current
amyloid tracers will bring to light important issues in the biology
of amyloid deposition in the transition from normal to AD.
CONCLUSION
Inthisreview,severalpotentialADbiomarkersindifferentmodal-
ities have been highlighted. Current data suggest that diagnosis
of AD can be enhanced by use of these promising biomark-
ers to increase accuracy and identify early stages of the disease.
Each of these biomarkers seems to indicate a speciﬁc process in
AD, so that amyloid imaging and decreased CSF Aβ42 are indi-
cators of brain amyloid burden, while CSF tau, brain atrophy
and brain metabolism are biomarkers of the neurodegenerative
process. Some authors have proposed a model of disease in which
there is timing for the use of different biomarkers (Jack et al.,
2010a). The AD pathologic cascade appears to have a sequential
two stage process initiated by amyloid accumulation and followed
by neuronal pathology. To validate this hypothesis and the right
use of biomarkers in the clinical practice, it is necessary to deter-
mine the dynamics of the amyloid process with other biomarkers
at the different stages of the disease. An early AD diagnosis could
enable to administer treatments with potential disease-modifying
effect before neurodegeneration becomes severe.
ACKNOWLEDGMENTS
Mario Riverol is supported by a grant from Fundación Caja
Madrid (Spain). Oscar L. López is supported in part by grants
AG200098 andAG05133-27 from the National Institute onAging.
Frontiers in Neurology | Dementia July 2011 | Volume 2 | Article 46 | 6Riverol and López AD biomarkers
REFERENCES
Aizenstein, H. J., Nebes, R. D., Sax-
ton, J. A., Price, J. C., Mathis, C.
A., Tsopelas, N. D., Ziolko, S. K.,
James, J. A., Snitz, B. E., Houck, P.
R., Bi, W., Cohen, A. D., Lopresti,
B. J., DeKosky, S. T., Halligan,
E. M., and Klunk, W. E. (2008).
Frequent amyloid deposition with-
outsigniﬁcantcognitiveimpairment
among the elderly. Arch. Neurol. 65,
1509–1517.
Albert, M. S., Dekosky, S. T., Dickson,
D., Dubois, B., Feldman, H. H., Fox,
N. C., Gamst, A., Holtzman, D. M.,
Jagust, W. J., Petersen, R. C., Snyder,
P. J., Carrillo, M. C., Thies, B., and
Phelps, C. H. (2011). The diagno-
sisofmildcognitiveimpairmentdue
to Alzheimer’s disease: recommen-
dations from the National Institute
on Aging and Alzheimer’s Associa-
tionworkgroup.AlzheimersDement.
7, 270–279.
Alexander, G. E., Chen, K., Pietrini, P.,
Rapoport, S. I., and Reiman, E. M.
(2002). Longitudinal PET evalua-
tion of cerebral metabolic decline
in dementia: a potential outcome
measureinAlzheimer’sdiseasetreat-
ment studies. Am. J. Psychiatry 159,
738–745.
Anchisi, D., Borroni, E., Franceschi,
M., Kerrouche, N., Kalbe, E.,
Beuthien-Beumann, B., and Cappa,
S. (2005). Heterogeneity of brain
glucose metabolism in mild cogni-
tive impairment and clinical pro-
gressiontoAlzheimer’sdisease.Arch.
Neurol. 62, 1728–1733.
Andreasen, N., Minthon, L., Davidson,
P., Vanmechelen, E., Vanderstichele,
H., Winblad, B., and Blennow, K.
(2001). Evaluation of CSF-tau and
CSF-alpha beta 42 as diagnostic
markers for Alzheimer disease in
clinical practice. Arch. Neurol. 58,
373–379.
Andreasen,N.,Minthon,L.,Vanmeche-
len, E., Vanderstichele, H., Davids-
son, P., Winblad, B., and Blennow,
K. (1999). Cerebrospinal ﬂuid tau
and Abeta42 as predictors of devel-
opment of Alzheimer’s disease in
patients with mild cognitive impair-
ment. Neurosci. Lett. 273, 5–8.
APA. (2000). Diagnostic and Statistical
Manual of Mental Disorders DSM-
IV-TR Fourth Edition (Text Revi-
sion). Washington, DC: American
Psychiatric Association.
Arai, H., Terajima, M., Miura, M.,
Higuchi, S., Muramatsu, T.,
Machida, N., Seiki, H., Takase,
S., Clark, C. M., and Lee, V. M.
(1995). Tau in cerebrospinal ﬂuid:
a potential diagnostic marker in
Alzheimer’sdisease.Ann.Neurol.38,
649–652.
Archer, H. A., Edison, P., Brooks, D.
J., Barnes, J., Frost, C., Yeatman,
T., Fox, N. C., and Rossor, M.
N. (2006). Amyloid load and cere-
bral atrophy in Alzheimer’s dis-
ease: an 11C-PIB positron emission
tomography study. Ann. Neurol. 60,
145–147.
Ashburner, J., and Friston, K. J. (2000).
Voxel-based morphometry – the
methods. Neurology 11, 805–821.
Ballard, C., Gauthier, S., Corbett,
A., Brayne, C., Aarsland, D., and
Jones,E.(2011).Alzheimer’sdisease.
Lancet 377, 1019–1031.
Barnes, J., Bartlett, J. W., van de Pol, L.
A., Loy, C. T., Scahill, R. I., Frost, C.,
Thompson,P.,andFox,N.C.(2009).
A meta-analysis of hippocampal
atrophy rates in Alzheimer’s disease.
Neurobiol. Aging 30, 1711–1723.
Becker, J. A., Hedden, T., Carmasin, J.,
Maye, J., Rentz, D. M., Putcha, D.,
Fischl, B., Greve, D. N., Marshall, G.
A., Salloway, S., Marks, D., Buckner,
R.L.,Sperling,R.A.,andJohnson,K.
A. (2010). Amyloid-beta associated
corticalthinninginclinicallynormal
elderly. Ann. Neurol. 69, 1032–1042.
Bell-McGinty, S., Lopez, O. L., Meltzer,
C. C., Scanlon, J. M., Whyte, E.
M., DeKosky, S. T., and Becker, J.
T. (2005). Differential cortical atro-
phy in subgroups of mild cogni-
tive impairment. Arch. Neurol. 62,
1393–1397.
Bian, H., Van Swieten, J. C., Leight, S.,
Massimo, L.,Wood, E., Forman, M.,
Moore, P., de Koning, I., Clark, C.
M., Rosso, S., Trojanowski, J., Lee,V.
M., and Grossman, M. (2008). CSF
biomarkers in frontotemporal lobar
degeneration with known pathol-
ogy. Neurology 70, 1827–1835.
Bibl, M., Mollenhauer, B., Esselmann,
H., Lewczuk, P., Klafki, H. W., Spar-
bier, K., Smirnov, A., Cepek, L.,
Trenkwalder, C., Ruther, E., Korn-
huber, J., Otto, M., and Wiltfang, J.
(2006). CSF amyloid-beta-peptides
in Alzheimer’s disease, dementia
with Lewy bodies and Parkin-
son’s disease dementia. Brain 129,
1177–1187.
Blennow, K., Hampel, H., Weiner, M.,
and Zetterberg, H. (2010). Cere-
brospinalﬂuidandplasmabiomark-
ers in Alzheimer disease. Nat. Rev.
Neurol. 6, 131–144.
Blennow, K., Wallin, A., Agren, H.,
Spenger, C., Siegfried, J., and Van-
mechelen, E. (1995). Tau protein
in cerebrospinal ﬂuid: a biochemi-
cal marker for axonal degeneration
in Alzheimer disease? Mol. Chem.
Neuropathol. 26, 231–245.
Bobinski, M., de Leon, M. J., Wegiel, J.,
Desanti, S., Convit, A., Saint Louis,
L. A., Rusinek, H., and Wisniewski,
H. M. (2000). The histological val-
idation of post mortem magnetic
resonance imaging-determined hip-
pocampal volume in Alzheimer’s
disease. Neuroscience 95, 721–725.




Bradley, K. M., O’Sullivan, V. T., Soper,
N. D. W., Nagy, Z., King, E. M.-
F., Smith, A. D., and Shepstone, B.
J. (2002). Cerebral perfusion SPET
correlated with Braak pathological
stage in Alzheimer’s disease. Brain
125, 1772–1781.
Brookmeyer, R., Gray, S., and Kawas,
C.(1998).ProjectionsofAlzheimer’s
disease in the United States and the
publichealthimpactof delayingdis-
ease onset. Am. J. Public Health 88,
1337–1342.
Brooks, L. G., and Loewenstein, D.
A. (2010). Assessing the progres-
sionofmildcognitiveimpairmentto
Alzheimer’s disease: current trends
and future directions. Alzheimers
Res. Ther. 2, 28.
Brys, M., Pirraglia, E., Rich, K., Rol-
stad, S., Mosconi, L., Switalski, R.,
Glodzik-Sobanska, L., De Santi, S.,
Zinkowski, R., Mehta, P., Pratico,
D., Saint Louis, L. A., Wallin, A.,
Blennow, K., and de Leon, M. J.
(2009). Prediction and longitudi-
nal study of CSF biomarkers in
mild cognitive impairment. Neuro-
biol. Aging 30, 682–690.
Buerger, K., Ewers, M., Pirttila, T.,
Zinkowski, R., Alafuzoff, I., Teipel,
S. J., DeBernardis, J., Kerkman, D.,
McCulloch, C., Soininen, H., and
Hampel, H. (2006a). CSF phospho-
rylated tau protein correlates with
neocortical neuroﬁbrillary pathol-
ogy in Alzheimer’s disease. Brain
129, 3035–3041.
Buerger, K., Otto, M., Teipel, S.
J., Zinkowski, R., Blennow, K.,
DeBernardis, J., Kerkman, D.,
Schroder,J.,Schonknecht,P.,Cepek,
L., McCulloch, C., Moller, H. J.,
Wiltfang, J., Kretzschmar, H., and
Hampel, H. (2006b). Dissociation
between CSF total tau and tau
protein phosphorylated at thre-
onine 231 in Creutzfeldt-Jakob
disease. Neurobiol. Aging 27,
10–15.
Buerger, K., Teipel, S. J., Zinkowski,
R., Blennow, K., Arai, H., Engel,
R.,Hoffmann-Kiefer,K.,McCulloch,
C., Ptok, U., Heun, R., Andreasen,
N., DeBernardis, J., Kerkman, D.,
Moeller, H.-J., Davies, P., and Ham-
pel,H.(2002).CSFtauproteinphos-
phorylated at threonine 231 corre-
lates with cognitive decline in MCI
subjects. Neurology 59, 627–629.
Burton, E. J., Barber, R., Mukaetova-
Ladinska, E. B., Robson, J., Perry,
R. H., Jaros, E., Kalaria, R. N., and
O’Brien, J. T. (2009). Medial tem-
poral lobe atrophy on MRI dif-
ferentiates Alzheimer’s disease from
dementia with Lewy bodies and
vascular cognitive impairment: a
prospective study with pathological
veriﬁcation of diagnosis. Brain 132,
195–203.
Cairns, N. J., Ikonomovic, M. D., Ben-
zinger, T., Storandt, M., Fagan, A.
M., Shah, A. R., Reinwald, L. T.,
Carter, D., Felton, A., Holtzman, D.
M., Mintun, M. A., Klunk, W. E.,
and Morris, J. C. (2009). Absence
of Pittsburgh compound B detec-
tion of cerebral amyloid beta in
a patient with clinical, cognitive,
and cerebrospinal ﬂuid markers of
Alzheimer disease: a case report.
Arch. Neurol. 66, 1557–1562.
Caselli, R. J., Chen, K., Lee, W., Alexan-
der,G.E.,andReiman,E.M.(2008).
Correlating cerebral hypometabo-
lism with future memory decline
in subsequent converters to amnes-
tic pre-mild cognitive impairment.
Arch. Neurol. 65, 1231–1236.
Chetelat, G., Desgranges, B., de la
Sayette, V., Viader, F., Eustache,
F., and Baron, J.-C. (2002). Map-
ping gray matter loss with voxel-
based morphometry in mild cog-
nitive impairment. Neuroreport 13,
1939–1943.
Chetelat, G., Desgranges, B., de la
Sayette, V., Viader, F., Eustache, F.,
and Baron, J.-C. (2003). Mild cog-
nitive impairment. Can FDG-PET
predict who is to rapidly convert to
Alzheimer’s disease? Neurology 60,
1374–1377.
Chetelat, G., Landeau, B., Eustache, F.,
Mezenge, F.,Viader, F., de la Sayette,
V., Desgranges, B., and Baron, J.
C. (2005). Using voxel-based mor-
phometry to map the structural
changes associated with rapid con-
version in MCI: a longitudinal MRI
study. Neuroimage 27, 934–946.
Chetelat,G.,Villemagne,V.L.,Bourgeat,
P., Pike, K. E., Jones, G., Ames,
D., Ellis, K. A., Szoeke, C., Mar-
tins, R. N., O’Keefe, G. J., Salvado,
O., Masters, C. L., and Rowe, C. C.
(2010). Relationship between atro-
phy and beta-amyloid deposition in
Alzheimer disease. Ann. Neurol. 67,
317–324.
Choi, S. R., Golding, G., Zhuang,
Z., Zhang, W., Lim, N., Hefti, F.,
Benedum, T. E., Kilbourn, M. R.,
Skovronsky, D., and Kung, H. F.
(2009).Preclinicalpropertiesof18F-
AV-45:aPETagentforAbetaplaques
in the brain. J. Nucl. Med. 50,
1887–1894.
www.frontiersin.org July 2011 | Volume 2 | Article 46 | 7Riverol and López AD biomarkers
Cruz de Souza, L., Lamari, F., Bel-
liard, S., Jardel, C., Houillier, C.,
De Paz, R., Dubois, B., and Sarazin,
M. (2011). Cerebrospinal ﬂuid bio-
markers in the differential diagno-
sis of Alzheimer’s disease from other
cortical dementias. J. Neurol. Neuro-
surg. Psychiatr. 82, 240–246.
de Leon, M. J., Convit, A., Wolf,
O. T., Tarshish, C. Y., DeSanti,
S., Rusinek, H., Tsui, W., Kandil,
E., Scherer, A. J., Roche, A.,
Imossi, A., Thorn, E., Bobinski,
M., Caraos, C., Lesbre, P., Schlyer,
D., Poirier, J., Reisberg, B., and
Fowler, J. (2001). Prediction of cog-
nitive decline in normal elderly sub-
jects with 2-[18F]ﬂuoro-deoxy-D-
glucose/positron-emission tomog-
raphy (FDG/PET). Proc. Natl. Acad.
Sci. U.S.A. 98, 10966–10971.
De Meyer, G., Shapiro, F., Vander-
stichele,H.,Vanmechelen,E.,Engel-
borghs, S., De Deyn, P. P., Coart,
E.,Hansson,O.,Minthon,L.,Zetter-
berg, H., Blennow, K., Shaw, L.,
and Trojanowski, J. Q. (2010).
Diagnosis-independent Alzheimer
disease biomarker signature in cog-
nitively normal elderly people. Arch.
Neurol. 67, 949–956.
Devanand, D. P., Pradhaban, G., Liu,
X.,Khandji,A.,DeSanti,S.,Segal,S.,
Rusineck,H.,Pelton,G.H.,Honig,L.
S., Mayeux, R., Stren, Y., Tabert, M.
H., and de Leon, M. J. (2007). Hip-
pocampal and entorhinal atrophy in
mild cognitive impairment. Predic-
tion of Alzheimer disease. Neurology
68, 828–836.
Dickerson, B. C., Bakkour, A., Salat, D.
H., Feczko, E., Pacheco, J., Greve,
D. N., Grodstein, F., Wright, C. I.,
Blacker, D., Rosas, H. D., Sperling,
R. A., Atri, A., Growdon, J. H.,
Hyman, B. T., Morris, J. C., Fis-
chl, B., and Buckner, R. L. (2008).
ThecorticalsignatureofAlzheimer’s
disease: regionally speciﬁc cortical
thinningrelatestosymptomseverity
in very mild to mild AD dementia







son, K. A., Viswanathan, A., Salat,
D. H., and Greenberg, S. M. (2010).
Spatial relation between microb-
leeds and amyloid deposits in amy-
loid angiopathy. Ann. Neurol. 68,
545–548.
Dougall, N. J., Bruggink, S., and
Ebmeier, K. P. (2004). System-
atic review of the diagnostic accu-
racyof99-m-Tc-HMPAO-SPECTin
dementia. Psychiatry 12, 554–570.
Drzezga, A., Grimmer, T., Riemen-
schneider, M., Lautenschlager,
N., Siebner, H., Alexopolous, P.,
Minoshima, S., Schwaiger, M.,
and Kurz, A. (2005). Prediction of
individual clinical outcome in MCI
by means of genetic assessment and
(18)-FDG PET. J. Nucl. Med. 46,
1625–1632.
Drzezga,A.,Lautenschlager,N.,Siebner,
H., Riemenschneider, M., Willoch,
F.,Minoshima,S.,Schwaiger,M.,and
Kurz, A. (2003). Cerebral metabolic
changes accompanying conversion
of mild cognitive impairment into
Alzheimer’s disease: a PET follow-
up study. E u r .J .N u c l .M e d .M o l .
Imaging 30, 1104–11013.
Du,A.T.,Schuff,N.,Amend,D.,Laakso,
M. P., Hsu, Y. Y., Jagust, W. J., Yaffe,
K., Framer, J. H., Reed, B., Nor-
man, D., Chui, H. C., and Weiner,
M. W. (2001). Magnetic resonance
imaging of the entorhinal cortex
and hippocampus in mild cognitive
impairment and Alzheimer’s dis-
ease. J. Neurol. Neurosurg. Psychiatr.
71, 441–447.
Dubois, B., Feldman, H. H., Jacova,
C.,Dekosky,S.T.,Barberger-Gateau,
P., Cummings, J., Delacourte, A.,
Galasko, D., Gauthier, S., Jicha, G.,
Meguro, K., O’Brien, J., Pasquier, F.,
Robert, P., Rossor, M., Salloway, S.,
Stern, Y., Visser, P. J., and Schel-
tens, P. (2007). Research criteria for
the diagnosis of Alzheimer’s dis-
ease: revising the NINCDS-ADRDA
criteria. Lancet Neurol. 6, 734–746.
Edison, P., Archer, A., Hinz, R., Ham-
mers,A.,Pavese,N.,Tai,Y.F.,Hotton,
G., Cutler, D., Fox, N. C., Kennedy,
A., Rossor, M., and Brooks, D. J.
(2006). Amyloid, hypometabolism,
and cognition in Alzheimer disease.
An [11C] PIB and [18F] FDG PET





Brooks, D. J. (2008). Amyloid load
in Parkinson’s disease dementia and
Lewy body dementia measured with
[11C]PIB positron emission tomog-
raphy. J. Neurol. Neurosurg. Psychi-
atr. 79, 1331–1338.
Engler, H., Forsberg, A., Almkvist, O.,
Blomquist, G., Larsson, E., Sav-
itcheva, I., Wall, A., Ringheim, A.,
Langstrom, B., and Nordberg, A.
(2006). Two-year follow-up of amy-
loid deposition in patients with
Alzheimer’s disease. Brain 129,
2856–2866.
Evans, M. C., Barnes, J., Nielsen, C.,
Kim, L. G., Clegg, S. L., Blair, M.,
Leung,K.K.,Douiri,A.,Boyes,R.G.,
Ourselin, S., and Fox, N. C. (2010).
Volume changes in Alzheimer’s dis-
easeandmildcognitiveimpairment:
cognitive associations. Eur. Radiol.
20, 674–682.




N., Wallin, A., DeBernardis, J.
F., Kerkman, D. J., Heindl, B.,
Blennow,K.,andHampel,H.(2007).
Multicenter assessment of CSF-
phosphorylated tau for the predic-
tion of conversion of MCI. Neurol-
ogy 69, 2205–2212.
Fagan, A. M., Head, D., Shah, A.
R., Marcus, D., Mintun, M., Mor-
ris, J. C., and Holtzman, D.
M. (2009). Decreased cerebrospinal
ﬂuid Abeta(42) correlates with
brain atrophy in cognitively normal
elderly. Ann. Neurol. 65, 176–183.
Fagan, A. M., Mintun, M. A., Mach,
R. H., Lee, S. Y., Dence, C. S.,
Shah, A. R., LaRossa, G. N., and
Spinner, M. L. (2006). Inverse rela-
tion between in vivo amyloid imag-
ing load and cerebrospinal ﬂuid
Abeta42inhumans.Ann.Neurol.59,
512–519.
Fagan, A. M., Roe, C. M., Xiong,
C., Mintun, M. A., Morris, J. C.,
and Holtzman, D. M. (2007). Cere-
brospinal ﬂuid tau/beta-amyloid12
ratio as a prediction of cogni-
tive decline in nondemented older
adults. Arch. Neurol. 64, 343–349.
Ferri, C. P., Prince, M., Brayne, C., Bro-
daty, H., Frataglioni, L., Ganguli,
M., Hall, K., Hasegawa, K., Hendrie,
H., Huang, Y., Jorm, A., Mathers,
C., Menezes, P. R., Rimmer, E., and
Scazufca, M. (2005). Global preva-
lence of dementia: a Delphi consen-
sus study. Lancet 366, 2112–2117.
Fjell, A. M., Walhovd, K. B., Fennema-
Notestine, C., McEvoy, L. K., Hagler,
D. J., Holland, D., Brewer, J. B., and
Dale, A. M. (2010). CSF biomarkers
in prediction of cerebral and clini-
cal change in mild cognitive impair-
ment and Alzheimer’s disease. J.
Neurosci. 30, 2088–2101.
Forsberg, A., Engler, H., Almkvist, O.,
Blomquist, G., Hagman, G., Wall,
A.,Ringheim,A.,Langstrom,B.,and
Nordberg,A.(2008).PETimagingof
amyloid deposition in patients with
mild cognitive impairment. Neuro-
biol. Aging 29, 1456–1465.
Foster, N. L., Chase, T. N., Mansi, L.,
Brooks, R., Fedio, P., Patronas, N.
J., and DiChiro, G. (1984). Cor-
tical abnormalities in Alzheimer’s
disease. Ann. Neurol. 16, 649–654.
Foster, N. L., Heidebrink, J. L., Clark,
C. M., Jagust, W. J., Arnold, S. E.,
Barbas,N. R.,DeCarli,C. S.,Turner,
R. S., Koeppe, R. A., Higdon, R.,
and Minoshima, S. (2007). FDG-
PET improves accuracy in distin-
guishing frontotemporal dementia
and Alzheimer’s disease. Brain 130,
2616–2635.
Galasko, D., Chang, L., Motter, R.,
Clark, C. M., Kaye, J., Knopman,
D., Thomas, R., Kholodenko, D.,
Schenk, D., Lieberburg, I., Miller,
B., Green, R., Basherad, R., Ker-
tiles, L., Boss, M. A., and Seubert, P.
(1998). High cerebrospinal ﬂuid tau
and low amyloid beta42 levels in the




DeKosky, S. T. (2004). Mild cogni-
tive impairment, amnestic type: an
epidemiologic study. Neurology 63,
115–121.
Geroldi, C., Rossi, R., Calvagna, C.,
Testa, C., Bresciani, L., Binetti, G.,
Zanetti, O., and Frisoni, G. B.
(2006).Medialtemporalatrophybut
not memory deﬁcit predicts pro-
gression to dementia in patients
with mild cognitive impairment.
J. Neurol. Neurosurg. Psychiatr. 77,
1219–1222.
Gomez-Isla, T., Hollister, R., West,




Ann. Neurol. 41, 17–24.
Gomperts, S. N., Rentz, D. M., Moran,
E.,Becker,J.A.,Locascio,J.J.,Klunk,
W. E., Mathis, C. A., Elmaleh, D. R.,
Shoup, T., Fischman, A. J., Hyman,
B. T., Growdon, J. H., and John-
son, K. A. (2008). Imaging amyloid
deposition in Lewy body diseases.
Neurology 71, 903–910.
Good, C. D., Scahill, R. T., Fox, N. C.,
Ashburner, J., Friston, K. J., Chan,
D., Grum, W. R., Rossor, M. N., and
Frackowiak, R. S. J. (2001). Auto-
matic differentiation of anatomi-
cal patterns in the human brain.
Validation with studies of degen-
erative dementias. Neuroimage 17,
29–46.
Grimmer, T., Riemenschneider, M.,
Forstl, H., Henriksen, G., Klunk, W.
E.,Mathis,C.A.,Shiga,T.,Wester,H.
J., Kurz, A., and Drzezga, A. (2009).
Beta amyloid in Alzheimer’s dis-
ease:increaseddepositioninbrainis
reﬂectedinreducedconcentrationin
cerebrospinal ﬂuid. Biol. Psychiatry
65, 927–934.
Gustafson, D. R., Skoog, I., Rosengren,
L., Zetterberg, H., and Blennow,
K. (2007). Cerebrospinal ﬂuid beta-
amyloid 1-42 concentration may
predict cognitive decline in older
women.J.Neurol.Neurosurg.Psychi-
atr. 78, 461–464.
Frontiers in Neurology | Dementia July 2011 | Volume 2 | Article 46 | 8Riverol and López AD biomarkers
Hall, A. M., Moore, R. Y., Lopez,
O. L., Kuller, L. H., and Becker,
J. T. (2008). Basal forebrain atro-
phy is a presymptomatic marker
for Alzheimer’s disease. Alzheimers
Dement. 4, 271–279.
Hampel, H., Buerger, K., Zinkowski, R.,
Teipel,S. J.,Goernitz,A.,Andreasen,
N., Sjoegren, M., DeBernardis, J.,
Kerkman,D.,Ishiguro,K.,Ohno,H.,
Vanmechelen,E.,Vanderstichele,H.,
McCulloch, C., Moller, H. J., Davies,
P., and Blennow, K. (2004a). Mea-
surementofphosphorylatedtauepi-
topes in the differential diagnosis
of Alzheimer disease: a comparative
cerebrospinal ﬂuid study. Arch. Gen.
Psychiatry 61, 95–102.
Hampel, H., Mitchell, A., Blennow,
K., Frank, R. A., Brettschneider, S.,
Weller, L., and Moller, H. J. (2004b).
Core biological marker candidates
of Alzheimer’sdisease–perspectives
fordiagnosis,predictionof outcome
and reﬂection of biological activity.
J. Neural Transm. 111, 247–272.
Hampel, H., Teipel, S. J., Fuchsberger,
T., Andreasen, N., Wiltfang, J., Otto,
M., Shen, Y., Dodel, R., Du, Y., Far-
low, M., Moller, H. J., Blennow, K.,
and Buerger, K. (2004c). Value of
CSF beta-amyloid1-42 and tau as
predictors of Alzheimer’s disease in
patients with mild cognitive impair-
ment. Mol. Psychiatry 9, 705–710.
Hampel, H., Burger, K., Pruessner, J. C.,
Zinkowski,R.,DeBernardis,J.,Kerk-
man,D.,Leinsinger,G.,Evans,A. C.,
Davies, P., Muller, H.-J., and Teipel,
S. J. (2005). Correlation of cere-
brospinal ﬂuid levels of tau protein
phosphorylated at threonine 231
with rates of hippocampal atrophy
in Alzheimer disease. Arch. Neurol.
62, 770–773.
Hansson, O., Zetterberg, H., Buch-
have, P., Londos, E., Blennow, K.,
and Minthon,L. (2006).Association
between CSF biomarkers and incip-
ient Alzheimer’s disease in patients
with mild cognitive impairment: a





and Barkhof, F. (2009). Hippocam-
pal atrophy rates in Alzheimer dis-
ease: added value over whole brain
volume measures. Neurology 72,
999–1007.
Huang, C., Eidelberg, D., Habeck, C.,
Moeller,J.,Svensson,L.,Tarabula,T.,
and Julin, P. (2007). Imaging mark-
ers of mild cognitive impairment:
multivariate analysis of CBF SPECT.
Neurobiol. Aging 28, 1062–1069.
Hulstaert, F., Blennow, K., Ivanoiu, A.,
Schoonderwaldt, H. C., Riemen-
schneider, M., De Deyn, P. P.,
Bancher, C., Cras, P., Wiltfang, J.,
Mehta, P. D., Iqbal, K., Pottel,
H., Vanmechelen, E., and Vander-
stichele, H. (1999). Improved dis-
crimination of AD patients using
beta-amyloid(1-42)andtaulevelsin
CSF. Neurology 52, 1555–1562.
Ikonomovic,M. D.,Klunk,W. E.,Abra-
hamson, E. E., Mathis, C. A., Price,
J. C., Tsopelas, N. D., Lopresti, B. J.,
Ziolko,S.,Bi,W.,Paljug,W. R.,Deb-
nath, M. L., Hope, C. E., Isanski, B.
A., Hamilton, R. L., and DeKosky, S.
T.(2008).Post-mortemcorrelatesof
in vivo PiB-PET amyloid imaging in




E. (2005). Voxel-based morphome-
tric comparison between early- and
late-onset mild Alzheimer’s disease
andassessmentof diagnosticperfor-
mance of z score images. AJNR Am.
J. Neuroradiol. 26, 333–340.
Ishii, K., Willoch, F., Minoshima, S.,
Drzezga, A., Ficaro, E. P., Cross, D.
J., Kuhl, D. E., and Schwaiger, M.
(2001). Statistical brain mapping of
18F-FDG PET in Alzheimer’s dis-
ease: validation of anatomic stan-
dardization for atrophied brains. J.
Nucl. Med. 42, 548–557.
Iwatsubo, T., Odaka, A., Suzuki, N.,
Mizusawa, H., Nukina, N., and
Ihara, Y. (1994). Visualization of A-
beta-42(43) and A-beta-40 in senile
plaques with end speciﬁc A-beta
monoclonals: evidence that an ini-
tially deposited species as A-beta-
42(43). Neuron 13, 45–53.
Jack, C., Petersen, R., Grundman, M.,
Jin, S., Gamst, A. C., Ward, C. P.,
Sencakova, D., Doody, R. S., and
Thal, L. J. (2008a). Longitudinal
MRIﬁndingsfromthevitaminEand
donepezil treatment study for MCI.
Neurobiol. Aging 29, 1285–1295.
Jack, C. R. Jr., Lowe, V. J., Senjem, M.
L., Weigand, S. D., Kemp, B. J., Shi-
ung, M. M., Knopman, D. S., Boeve,
B. F., Klunk, W. E., Mathis, C. A.,
andPetersen,R.C.(2008b).11CPiB
and structural MRI provide com-
plementary information in imaging
of Alzheimer’s disease and amnes-
ticmildcognitiveimpairment.Brain
131, 665–680.
Jack, C. R. Jr., Knopman, D. S., Jagust,
W. J., Shaw, L. M., Aisen, P. S.,
Weiner, M. W., Petersen, R. C., and
Trojanowski, J. Q. (2010a). Hypo-
thetical model of dynamic biomark-
ers of the Alzheimer’s pathological
cascade. Lancet Neurol. 9, 119–128.
Jack, C. R. Jr., Wiste, H. J., Vemuri, P.,
Weigand,S. D.,Senjem,M. L.,Zeng,
G., Bernstein, M. A., Gunter, J. L.,
Pankratz, V. S., Aisen, P. S., Weiner,
M. W., Petersen, R. C., Shaw, L. M.,
Trojanowski, J. Q., and Knopman,
D. S. (2010b). Brain beta-amyloid
measures and magnetic resonance
imaging atrophy both predict time-
to-progression from mild cognitive
impairment to Alzheimer’s disease.
Brain 133, 3336–3348.
Jack, C. R. Jr., Lowe, V. J., Weigand,
S. D., Wiste, H. J., Senjem, M. L.,
Knopman, D. S., Shiung, M. M.,
Gunter, J. L., Boeve, B. F., Kemp, B.
J., Weiner, M., and Petersen, R. C.
(2009). Serial PIB and MRI in nor-
mal,mild cognitive impairment and
Alzheimer’sdisease:implicationsfor
sequence of pathological events
in Alzheimer’s disease. Brain 132,
1355–1365.
Jack, C. R., Petersen, R. C., Xu, Y.,
O’Brien, P. C., Smith, G. E., Ivnik,
R. J., Boeve, B. F., Tangalos, E. G.,
and Kokmen, E. (2000). Rates of
hippocampal atrophy correlate with
changeinclinicalstatusinagingand
AD. Neurology 55, 484–489.
Jack, C. R., Petersen, R. C., Xu, Y. C.,
O’Brien, P. C., Smith, G. E., Ivnik,
R. J., Boeve, B. F., Waring, S. C.,
Tangalos, E. G., and Kokmen, E.
(1999). Prediction of AD aith MRI-
based hippocampal volume in mild
cognitiveimpairment.Neurology 52,
1397–1403.
Jack, C. R., Shiung, M. M., Gunter, J. L.,
O’Brien,P.C.,Weigand,S.D.,Knop-
man, D. S., Boeve, B. F., Ivnik, R.
J., Smith, G. E., Cha, R. H., Tanga-
los,E.G.,andPetersen,R.C.(2004).
Comparison of different MRI brain
atrophy rate measures with clinical
diseaseprogressioninAD.Neurology
62, 591–600.
Jagust, W., Thisted, R., Devous, M.
D., Van Heertum, R., Mayberg, H.,
Jobst, K., Smith, A. D., and Borys,
N. (2001). SPECT perfusion imag-
ing in the diagnosis of Alzheimer’s
disease: a clinical-pathologic study.
Neurology 56, 950–956.
Jagust, W., Zheng, L., Harvey, D. J.,
Mack,W.J.,Vinters,H.V.,Weiner,M.
W., Ellis,W. G., Zarrow, C., Mungas,
D., and Reed, B. R. (2008). Neu-
ropathologicalbasisofmagneticres-
onance images in aging and demen-
tia. Ann. Neurol. 63, 72–80.
Jagust,W.J.,Gitcho,A.,Sun,F.,Kuczyn-
ski, B., Mungas, D., and Haan,
M. (2006). Brain imaging evidence
of preclinical Alzheimer’s disease
in normal aging. Ann. Neurol. 59,
673–681.
Jagust, W. J., Landau, S. M., Shaw, L.
M., Trojanowski, J. Q., Koeppe, R.
A., Reiman, E. M., Foster, N. L.,
Petersen,R. C.,Weiner,M.W.,Price,
J. C., and Mathis, C. A. (2009).
Relationships between biomarkers
in aging and dementia. Neurology
73, 1193–1199.
Kadir, A., Almkvist, O., Forsberg, A.,
Wall, A., Engler, H., Langstrom,
B., and Nordberg, A. (2010).
Dynamic changes in PET amy-
loid and FDG imaging at differ-
ent stages of Alzheimer’s disease.
Neurobiol. Aging. doi: 10.1016/j.
neurobiolaging.2010.06.015. [Epub
ahead of print].
Kapaki, E., Kilidireas, K., Paraskevas,
G. P., Michalopoulou, M., and Pat-
souris, E. (2001). Highly increased
CSF tau protein and decreased beta-
amyloid (1-42) in sporadic CJD:




N. G., Sfagos, C., Seretis, A., Karari-
zou,E.,andVassilopoulos,D.(2007).
Cerebrospinal ﬂuid tau, phospho-
tau181 and beta-amyloid1-42 in
idiopathic normal pressure hydro-
cephalus: a discrimination from
Alzheimer’s disease. Eur. J. Neurol.
14, 168–173.
Karas, G. B., Burton, E. J., Rombouts,
S. A. R. B., van Schijndel, R. A.,
O’Brien, J. T., Scheltens, P. H., McK-
eith, I. G., Williams, D., Ballard, C.,
and Barkhof, F. (2003). A compre-
hensive study of gray metter loss
in patients with Alzheimer’s disease
using optimized voxel-based mor-
phometry. Neuroimage 18,895–907.
Karas, G. B., Scheltens, P., Rombouts,
S. A. R. B., Visser, P. J., van Schijn-






man, F. H., van Elk, E. J., Scheltens,
P., and van der Flier, W. M. (2009).
CSF biomarkers in Alzheimer’s dis-
ease and controls: associations with
APOEgenotypearemodiﬁedbyage.
J. Alzheimers Dis. 16, 601–607.
Klunk, W. E. (1998). Biological mark-
ersofAlzheimer’sdisease.Neurobiol.
Aging 19, 145–147.
Klunk, W. E., Engler, H., Nord-
berg, A., Wang, Y., Blomqvist, G.,
Holt, D. P., Bergström, M., Sav-
itcheva, I., Huang, G., and Estrada,
S. (2004). Imaging brain amyloid
in Alzheimer’s disease with Pitts-
burgh compound-B. Ann. Neurol.
55, 306–319.
Klunk, W. E., Wang, Y., Huang, G. F.,
Debnath, M. L., Holt, D. P., Shao,
L., Hamilton, R. L., Ikonomovic,
M. D., DeKosky, S. T., and Mathis,
C. A. (2003). The binding of 2-(4 -
methylaminophenyl)benzothiazole
to postmortem brain homogenates
is dominated by the amyloid
component. J. Neurosci. 23,
2086–2092.
www.frontiersin.org July 2011 | Volume 2 | Article 46 | 9Riverol and López AD biomarkers
Knopman, D. S., DeKosky, S. T., Cum-
mings, J. L., Chui, H., Corey-
Bloom, J., Relkin, N., Small, G.
W., Miller, B., and Stevens, J. C.
(2001). Practice parameter: diagno-
sis of dementia (an evidence-based
review). Report of the Quality Stan-
dards Subcommittee of the Ameri-
can Academy of Neurology. Neurol-
ogy 56, 1143–1153.
Koeppe,R. A.,Gilman,S.,Joshi,A.,Liu,
S., Little, R., Junck, L., Heumann,
M., Frey, K. A., and Albin, R.
L. (2005). 11C-DTBZ and 18F-
FDG PET measures in differenti-
ating dementias. J. Nucl. Med. 46,
936–944.
Kogure, D., Matsuda, H., Ohnishi, T.,
Kumihiro,T.,Uno,M.,andTakasaki,
M. (2000). Longitudinal evaluation
of early Alzheimer disease using
brainperfusionSPECT.J.Nucl.Med.
41, 1155–1162.
Koivunen, J., Scheinin, N., Virta, J.
R., Aalto, S., Vahlberg, T., Nagren,
K., Helin, S., Parkkola, R., Viita-
nen, M., and Rinne, J. O. (2011).
Amyloid PET imaging in patients
withmildcognitiveimpairment:a2-
year follow-up study. Neurology 76,
1085–1090.
Koopman, K., Le Bastard, N., Mar-
tin, J. J., Nagels, G., De Deyn, P.
P., and Engelborghs, S. (2009).
Improved discrimination of
autopsy-conﬁrmed Alzheimer’s dis-
ease (AD) from non-AD dementias
using CSF P-tau(181P). Neurochem.
Int. 55, 214–218.
Kudo, Y., Okamura, N., Furumoto,
S., Tashiro, M., Furukawa, K.,
Maruyama, M., Itoh, M., Iwata,
R., Yanai, K., and Arai, H. (2007).
2-(2-[2-Dimethylaminothiazol-5-
yl]ethenyl)-6-(2-[ﬂuoro]ethoxy)
benzoxazole: a novel PET agent for
in vivo detection of dense amyloid
plaques in Alzheimer’s disease
patients. J. Nucl. Med. 48, 553–561.
Kurz,A.,Riemenschneider,M.,Buch,K.,
Willoch, F., Bartenstein, P., Muller,
U., and Guder, W. (1998). Tau pro-
tein in cerebrospinal ﬂuid is sig-
niﬁcantly increased at the earliest
clinical stage of Alzheimer’s dis-
ease.AlzheimerDis.Assoc.Disord.12,
372–377.
Lee, V. M. Y. (1996). Regulation of
tau phosphorylation in Alzheimer’s
disease. Ann. N. Y. Acad. Sci. 777,
107–113.
Leinonen,V.,Alafuzoff,I.,Aalto,S.,Suo-
tunen, T., Savolainen, S., Nagren,
K., Tapiola, T., Pirttila, T., Rinne,
J., Jaaskelainen, J. E., Soininen, H.,
and Rinne, J. O. (2008). Assess-
ment of beta-amyloid in a frontal
cortical brain biopsy specimen and
by positron emission tomography
with carbon 11-labeled Pittsburgh
compound B. Arch. Neurol. 65,
1304–1309.
Lewczuk, P., Esselmann, H., Otto, M.,
Maler, J. M., Henkel, A. W., Henkel,
M. K., Eikenberg, O., Antz, C.,
Krause, W.-R., and Reulbach, U.
(2004). Neurochemical diagnosis of
Alzheimer’s dementia by CSF AB42,
AB42/AB40ratioandtotaltau.Neu-
robiol. Aging 25, 273–281.
Lim,A.,Tsuang,D.,Kukull,W.,Nochlin,
D., Leverena, J., McCormick, W.,
Bowen, J., Teri, L., Thompson,
J., Peskind, E. R., Raskind, M.,
and Larson, E. B. (1999). Clinico-
neuropathological correlation of
Alzheimer’sdiseaseinacommunity-
based case series. J. Am. Geriatr. Soc.
47, 564–569.
Mathis, C. A., Bacskai, B. J., Kajdasz, S.
T., McLellan, M. E., Frosch, M. P.,
Hyman, B. T., Holt, D. P., Wang, Y.,
Huang, G. F., Debnath, M. L., and
Klunk, W. E. (2002). A lipophilic
thioﬂavin-T derivative for positron
emission tomography (PET) imag-
ingof amyloidinbrain.Bioorg.Med.
Chem. Lett. 12, 295–298.
Mathis,C.A.,Lopresti,B. J.,and Klunk,
W. E. (2007). Impact of amyloid
imaging on drug development in
Alzheimer’s disease. Nucl. Med. Biol.
34, 809–822.
Mathis, C. A., Wang, Y., Holt, D.
P., Huang, G. F., Debnath, M. L.,
and Klunk, W. E. (2003). Synthe-
sis and evaluation of 11C-labeled 6-
substituted 2-arylbenzothiazoles as
amyloid imaging agents. J. Med.
Chem. 46, 2740–2754.
Mattsson, N., Zetterberg, H., Hansson,
O., Andreasen, N., Parnetti, L., Jon-
sson, M., Herukka, S. K., van der
Flier, W. M., Blankenstein, M. A.,
Ewers, M., Rich, K., Kaiser, E., Ver-
beek, M., Tsolaki, M., Mulugeta, E.,
Rosen, E., Aarsland, D., Visser, P. J.,
Schroder, J., Marcusson, J., de Leon,
M., Hampel, H., Scheltens, P., Pirt-
tila, T., Wallin, A., Jonhagen, M.
E., Minthon, L., Winblad, B., and
Blennow,K.(2009).CSFbiomarkers
and incipient Alzheimer disease in
patients with mild cognitive impair-
ment. JAMA 302, 385–393.
Mayeux, R., Saunders, A. M., Shea, S.,
Mirra, S., Evans, D., Roses, A. D.,
Hyman, B. T., Crain, B., Tang, M.,
and Phelps, C. H. (1998). Utility of
theapolipoproteinEgenotypeinthe
diagnosisof Alzheiemer’sdisease.N.
E n g l .J .M e d .338, 506–511.
McKhann, G., Drachman, D. A., Fol-
stein, M. F., Katzman, R., Price,
D. L., and Stadlan, E. (1984).
Clinical diagnosis of Alzheimer’s
disease: report of the NINCDS-
ADRDAWorkGroupundertheaus-
pices of the Department of Health
and Human Services Task Force on
Alzheimer’s disease. Neurology 34,
939–944.
McKhann, G. M., Knopman, D. S.,
Chertkow, H., Hyman, B. T., Jack,
C. R. Jr., Kawas, C. H., Klunk, W.
E., Koroshetz, W. J., Manly, J. J.,
Mayeux, R., Mohs, R. C., Morris, J.
C., Rossor, M. N., Scheltens, P., Car-
illo, M. C., Thies, B., Weintraub, S.,
and Phelps, C. H. (2011). The diag-
nosisofdementiaduetoAlzheimer’s
disease: recommendations from the
National Institute on Aging and the
Alzheimer’s Association workgroup.
Alzheimers Dement. 7, 263–269.
Minoshima,S.,Foster,N.L.,Sima,A.A.,
Frev, K. A., Albin, R. L., and Kuhl,
D. E. (2001). Alzheimer’s disease
versus dementia with Lewy bodies:
cerebral metabolic distinction with
autopsy conﬁrmation. Ann. Neurol.
50, 358–365.
Minoshima, S., Frey, K. A., Koeppe,
R. A., Foster, N. L., and Kuhl, D.
E. (1995). A diagnostic approach
in Alzheimer’s disease using three-
dimensional stereotactic surface
projections of ﬂuorine-18-FDG
PET. J. Nucl. Med. 36, 1238–1248.
Minoshima, S., Giordani, B., Berent, S.,
Frey, K. A., Foster, N. L., and Kuhl,
D. E. (1997). Metabolic reduction
in the posterior congulare cortex in





S. T., and Morris, J. C. (2006).
[11C]PIB in a nondemented popu-
lation: potential antecedent marker
of Alzheimer disease. Neurology 67,
446–452.
Mitchell, A. J. (2009). CSF phosphory-
lated tau in the diagnosis and prog-
nosis of mild cognitive impairment
and Alzheimer’s disease: a meta-
analysis of 51 studies. J. Neurol.
Neurosurg. Psychiatr. 80, 966–975.
Mormino, E. C., Kluth, J. T., Madison,
C. M.,Rabinovici,G. D.,Baker,S. L.,
Miller, B. L., Koeppe, R. A., Mathis,
C. A., Weiner, M. W., and Jagust,
W. J. (2009). Episodic memory loss
is related to hippocampal-mediated
beta-amyloid deposition in elderly
subjects. Brain 132, 1310–1323.
Morris, J. C., Roe, C. M., Grant, E.
A., Head, D., Storandt, M., Goate,
A., Fagan, A. M., Holtzman, D. M.,
and Mintun, M. A. (2009). Pitts-
burgh compound B imaging and
prediction of progression from cog-
nitive normality to symptomatic
Alzheimer disease. Arch. Neurol. 66,
1469–1475.
Morris, J. C., Roe, C. M., Xiong, C.,
Fagan, A. M., Goate, A. M., Holtz-
man, D. M., and Mintun, M. A.
(2010).APOEpredictsamyloid-beta
but not tau Alzheimer pathology
in cognitively normal aging. Ann.
Neurol. 67, 122–131.
Mortimer, J. A., Gosche, K. M., Riley,
K. P., Markesbery, W. R., and
Snowdon, D. A. (2004). Delayed





W., De Santi, S., and de Leon, M.
J. (2007). Maternal family history
of Alzheimer’s disease predisposes
to reduced brain glucose metabo-
lism.Proc.Natl.Acad.Sci.U.S.A.104,
19067–19072.
Mosconi, L., De Santi, S., Li, J., Tsui,
W. H., Li, Y., Boppana, M., Laska,
E., Rusinek, H., and de Leon, M. J.
(2008). Hippocampal hypometabo-
lism predicts cognitive decline from
normal aging. Neurobiol. Aging 29,
676–692.
Mosconi, L., Mistur, R., Switalski, R.,
Brys, M., Glodzik, L., Rich, K., Pir-
raglia, E., Tsui, W., De Santi, S., and
de Leon, M. J. (2009). Declining
brain glucose metabolism in normal
individuals with a maternal history
of Alzheimer disease. Neurology 72,
513–520.
Mosconi, L., Tsui, E. H., De Santi, S., Li,
J.,Rusinek,H.,Convit,A.,Li,Y.,Bop-
pana, M., and de Leon, M. J. (2005).
Reduced hippocampal metabolism
in MCI and AD. Automated FDG-
PET image analysis. Neurology 64,
1860–1867.
Motter, R., Vigo-Pelfrey, C., Kholo-
denko, D., Barbour, R., Johnson-
Wood, K., Galasko, D., Chang, L.,
Miller, B., Clark, C., and Green,
R. (1995). Reduction of beta-
amyloid peptide42 in the cere-
brospinal ﬂuid of patients with
Alzheimer’sdisease.Ann.Neurol.38,
643–648.
Mukaetova-Ladinska, E. B., Monteith,
R., and Perry, E. K. (2010).
Cerebrospinal ﬂuid biomarkers for
dementia with Lewy bodies. Int. J.
Alzheimers Dis. 2010, 536538.
Mulugeta, E., Londos, E., Ballard, C.,
Alves, G., Zetterberg, H., Blennow,
K., Skogseth, R., Minthon, L., and
Aarsland, D. (2010). CSF amyloid
beta38 as a novel diagnostic marker
for dementia with Lewy bodies.
J. Neurol. Neurosurg. Psychiatr. 82,
160–164.
O’Brien, J. T., Paling, S., Barber, R.,
Williams, E. D., Ballard, C., McK-
eith, I. G., Gholkar, A., Crum, W.
R., Rossor, M. N., and Fox, N.
C. (2001). Progressive brain atro-
phy on serial MRI in demen-
tia with Lewy bodies, AD, and
vascular dementia. Neurology 56,
1386–1388.
Frontiers in Neurology | Dementia July 2011 | Volume 2 | Article 46 | 10Riverol and López AD biomarkers
Okello, A., Koivunen, J., Edison, P.,
Archer, H. A., Turkheimer, F. E.,
Nagren, K., Bullock, R., Walker, Z.,
Kennedy, A., Fox, N. C., Rossor, M.
N., Rinne, J. O., and Brooks, D. J.
(2009). Conversion of amyloid pos-
itive and negative MCI to AD over 3
years: an 11C-PIB PET study. Neu-
rology 73, 754–760.
Panegyres, P. K., Rogers, J. M.,
McCarthy, M., Campbell,
A., and Wu, J. S. (2009).
Fluorodeoxyglucose-positron emis-
sion tomography in the differential
diagnosis of early-onset dementia:
a prospective, community-based
study. BMC Neurol. 9, 41. doi:
10.1186/1471-2377-9-41
Patwardhan, M. B., McCrory, D. C.,
Matchar, D. B., Samsa, G. P.,
and Rutschmann, O. T. (2004).
Alzheimer disease: operating char-
acteristics of PET-a meta-analysis.
Radiology 231, 73–80.
Pennanen, C., Kivipelto, M., Tuo-
mainen, S., Hartikainen, P., Hanni-
nen,T.,Laakso,M.P.,Hallikainen,V.,
Vanhanen,M.,Nissinen,A.,Helkala,
E.-L., Vainio, P., Vanninen, R., Par-
tanen, K., and Soininen, H. (2004).
Hippocampus and entorhinal cor-
tex in mild cognitive impairment
and early AD. Neurobiol. Aging 25,
303–310.
Peskind, E. R., Li, G., Shofer, J., Quinn,
J. F., Kaye, J. A., Clark, C. M., Far-
low, M. R., DeCarli, C., Raskind,
M. A., Schellenberg, G. D., Lee, V.
M., and Galasko, D. R. (2006). Age
and apolipoprotein E*4 allele effects
on cerebrospinal ﬂuid beta-amyloid
42 in adults with normal cognition.
Arch. Neurol. 63, 936–939.
Petersen, R. C., Roberts, R. O., Knop-
man, D. S., Boeve, B. F., Geda, Y. E.,
Ivnik,R. J.,Smith,G. E.,and Jack,C.
R. Jr. (2009). Mild cognitive impair-
ment: ten years later. Arch. Neurol.
66, 1447–1455.
Petrie, E. C., Cross, D. J., Galasko, D.,
Schellenberg, G. D., Raskind, M.
A., Peskind, E. R., and Minoshima,
S. (2009). Preclinical evidence of
Alzheimerchanges:convergentcere-
brospinal ﬂuid biomarker and ﬂu-
orodeoxyglucose positron emission
tomography ﬁndings. Arch. Neurol.
66, 632–637.
Pike, K. E., Savage, G., Villemagne, V.
L., Ng, S., Moss, S. A., Maruff, P.,
Mathis,C. A.,Klunk,W. E.,Masters,
C. L., and Rowe, C. C. (2007). Beta-
amyloid imaging and memory in
non-dementedindividuals:evidence
for preclinical Alzheimer’s disease.
Brain 130, 2837–2844.
Price,J.L.,andMorris,J.C.(1999).Tan-
gles and plaques in nondemented
aging and “preclinical” Alzheimer’s
disease. Ann. Neurol. 45, 358–368.
Querfurth, H. W., and LaFerla, F. M.
(2010). Alzheimer’s disease. N. Engl.
J. Med. 362, 329–344.
Raji, C. A., Lee, C., Lopez, O. L., Tsay, J.,
Boardman,J.F.,Schwartz,E.D.,Bar-
tynski,W. S., Hefzy, H. M., Gach, H.
M.,Dai,W.,and Becker,J. T. (2010).
Initial experience in using continu-
ous arterial spin-labeled MR imag-
ing for early detection of Alzheimer
disease.AJNRAm.J.Neuroradiol.31,
847–855.
Reiman, E. M., Caselli, R. J., Chen,
K., Alexander, G. E., Bandy, D.,
and Frost, J. (2001). Declining
brain activity in cognitively nor-
mal apolipoprotein E epsilon 4 het-
erozygotes: a foundation for using
positron emission tomography to
efﬁciently test treatments to prevent
Alzheimer’sdisease.Proc.Natl.Acad.
Sci. U.S.A. 98, 3334–3339.
Reiman, E. M., Caselli, R. J., Yun, L.
S., Chen, K., Bandy, D., Minoshima,
S., Thibodeau, S. N., and Osborne,
D. (1996). Preclinical evidence
of Alzheimer’s disease in persons
homozygous for the epsilon 4 allele
forapolipoproteinE.N.Engl.J.Med.
334, 752–758.
Reiman, E. M., Chen, K., Alexander, G.
E., Caselli, R. J., Bandy, D., Osborne,
D., Saunders, A. M., and Hardy, J.
(2004). Functional brain abnormal-
ities in young adults at genetic risk
for late-onset Alzheimer’s demen-
tia. Proc. Natl. Acad. Sci. U.S.A. 101,
284–289.
Reiman, E. M., Chen, K., Alexan-
der, G. E., Caselli, R. J., Bandy,
D., Osborne, D., Saunders, A. M.,
and Hardy, J. (2005). Correlations
between apolipoprotein E epsilon4
gene dose and brain-imaging mea-
surements of regional hypometabo-
lism.Proc.Natl.Acad.Sci.U.S.A.102,
8299–8302.
Rentz, D. M., Locascio, J. J., Becker, J.
A., Moran, E. K., Eng, E., Buckner,
R. L., Sperling, R. A., and Johnson,
K.A.(2010).Cognition,reserve,and
amyloiddepositioninnormalaging.
Ann. Neurol. 67, 353–364.
Ridha, B. H., Anderson, V. M., Barnes,
J., Boyes, R. G., Price, S. L., Rossor,
M. N., Whitwell, J. L., Jenkins, L.,
Black, R. S., Grundman, M., and
Fox, N. C. (2008). Volumetric MRI
andcognitivemeasuresinAlzheimer
disease: comparison of markers of
progression.J.Neurol.255,567–574.
Riemenschneider, M., Wagenpfeil, S.,
Diehl, J., Lautenschlager, N., Theml,
T., Heldmann, B., Drzezga, A.,
Jahn, T., Forstl, H., and Kurz, A.
(2002). Tau and A-beta-42 protein
in CSF of patients with frontotem-
poral degeneration. Neurology 58,
1622–1628.
Riemenschneider, M., Wagenpfeil, S.,
Vanderstichele, H., Otto, M., Wilt-
fang, J., Kretzschmar, H., Van-
mechelen, E., Forstl, H., and Kurz,
A. (2003). Phospho-tau/total tau
ratioincerebrospinalﬂuiddiscrimi-
natesCreutzfeldt-Jakobdiseasefrom
other dementias. Mol. Psychiatry 8,
343–347.
Rowe, C. C., Ackerman, U., Browne,
W., Mulligan, R., Pike, K. L.,
O’Keefe, G., Tochon-Danguy, H.,
Chan, G., Berlangieri, S. U., Jones,
G.,Dickinson-Rowe,K. L.,Kung,H.
P.,Zhang,W.,Kung,M. P.,Skovron-
sky, D., Dyrks, T., Holl, G., Krause,
S., Friebe, M., Lehman, L., Linde-
mann, S., Dinkelborg, L. M., Mas-
ters, C. L., and Villemagne, V. L.
(2008). Imaging of amyloid beta
in Alzheimer’s disease with 18F-
BAY94-9172, a novel PET tracer:
proof of mechanism. Lancet Neurol.
7, 129–135.
Rowe, C. C., Ng, S., Ackermann, U.,
Gong, S. J., Pike, K., Savage, G.,
Cowie, T. F., Dickinson, K. L.,
Maruff, P., and Darby, D. (2007).
Imaging beta-amyloid burden in
aging and dementia. Neurology 68,
1718–1725.
Scheinin,N. M.,Aalto,S.,Koikkalainen,
J., Lotjonen, J., Karrasch, M., Kemp-
painen, N., Viitanen, M., Nagren,
K., Helin, S., Scheinin, M., and
Rinne, J. O. (2009). Follow-up of
[11C]PIB uptake and brain vol-
ume in patients with Alzheimer dis-




E. J., Van Kamp, G. J., Van Swieten,
J. C., and Scheltens, P. (2004). Amy-
loid beta (1-42) and phosphorylated
tau in CSF as markers for early-
onset Alzheimer disease. Neurology
62, 1580–1584.
Schott, J. M., Bartlett, J. W., Fox, N.
C., and Barnes, J. (2010). Increased
brain atrophy rates in cognitively
normal older adults with low cere-
brospinal ﬂuid A beta1-42. Ann.
Neurol. 68, 825–834.
Schott, J. M., Crutch, S. J., Frost,
C., Warrington, E. K., Rossor,
M. N., and Fox, N. C. (2008).
Neuropsychological correlates of





Petersen, R. C., Blennow, K., Soares,
H.,Simon,A.,Lewczuk,P.,Dean,R.,
Siemers, E., Potter, W., Lee, V. M.,
and Trojanowski,J. Q. (2009). Cere-
brospinal ﬂuid biomarker signature
inAlzheimer’sdiseaseneuroimaging
initiative subjects. Ann. Neurol. 65,
403–413.
Shin, J., Lee, S. Y., Kim, S. H., Kim,
Y. B., and Cho, S. J. (2008). Mul-
titracer PET imaging of amyloid
plaques and neuroﬁbrillary tangles
in Alzheimer’s disease. Neuroimage
43, 236–244.
Shoji, M., Matsubara, E., Kanai, M.,
Watanabe, M., Nakamura, T., Tomi-
dokoro, Y., Shizuka, M., Wak-
abayashi, K., Igeta, Y., Ikeda, Y.,
Mizushima, K.,Amari, M., Ishiguro,
K., Kawarabayasi, T., Harigaya, Y.,
Okamoto, K., and Hirai, S. (1998).
Combination assay of CSF tau, A
beta 1-40 and A beta 1-42(43) as
a biochemical marker of Alzheimer
disease. J. Neurol. Sci. 158, 134–140.
Silverman, D. H., Small, G. W., Chang,
C. Y., Lu, C. S., DeAburto, K.,
Chen, W., Czernin, J., Rapoport, S.
I., Petrini, P., and Alexander, G. E.
(2001). Positron emission tomog-
raphy in evaluation of demen-
tia: regional brain metabolism and
long-term outcome. JAMA 286,
2120–2127.
Sluimer,J.D.,vanderFlier,W.M.,Karas,
G. B., Fox, N. C., Scheltens, P., Bark-
hof, F., and Vrenken, H. (2008a).
Whole-brainatrophyrateandcogni-
tive decline: longitudinal MR study
of memoryclinicpatients.Radiology
248, 590–598.
Sluimer, J. D., Vrenken, H., Blanken-
stein, M. A., Fox, N. C., Scheltens,
P., Barkhof, F., and van der Flier,
W.M.(2008b).Whole-brainatrophy
rate in Alzheimer disease: identify-
ing fast progressors. Neurology 70,
1836–1841.
Small,G.W.,Kepe,V.,Ercoli,L.M.,Sid-
darth, P., Bookheimer, S. Y., Miller,
K. J., Lavretsky, H., Burggren, A.
C., Cole, G. M., Vinters, H. V., and
Thompson, P. M. (2006). PET of
brain amyloid and tau in mild cog-
nitive impairment. N .E n g l .J .M e d .
355, 2652–2663.
Sperling, R. A., Aisen, P. S., Beckett, L.
A.,Bennett,D.A.,Craft,S.,Fagan,A.
M.,Iwatsubo,T.,Jack,C. R.,Kaye,J.,
Montine, T. J., Park, D. C., Reiman,
E.M.,Rowe,C.C.,Siemers,E.,Stern,
Y.,Yaffe,K.,Carrillo,M.C.,Thies,B.,
Morrison-Bogorad, M., Wagster, M.
V.,and Phelps,C. H. (2011). Toward
deﬁning the preclinical stages of
Alzheimer’s disease: recommenda-
tions from the National Institute on
Aging and the Alzheimer’s Associa-
tionworkgroup.AlzheimersDement.
7, 280–292.
www.frontiersin.org July 2011 | Volume 2 | Article 46 | 11Riverol and López AD biomarkers
Spulber, G., Niskanen, E., Macdonald,
S., Smilovici, O., Chen, K., Reiman,
E. M., Jauhiainen, A. M., Hal-
likainen, M., Tervo, S., Wahlund, L.
O., Vanninen, R., Kivipelto, M., and
Soininen, H. (2008). Whole brain
atrophy rate predicts progression
from MCI to Alzheimer’s disease.
Neurobiol. Aging 31, 1601–1605.
Stomrud, E., Hansson, O., Blennow, K.,
Minthon, L., and Londos, E. (2007).
Cerebrospinal ﬂuid biomarkers pre-
dict decline in subjective cognitive
function over 3 years in healthy
elderly. Dement. Geriatr. Cogn. Dis-
ord. 24, 118–124.
Stornadt, M., Mintun, M. A., Head, D.,
and Morris, J. C. (2009). Cognitive
decline and brain volume loss as
signatures of cerebral amyloid-beat
peptide deposition identiﬁed with
Pittsburgh compound B: cognitive
decline associated with Abeta depo-
sition. Arch. Neurol. 66, 1476–1481.
Strozyk, D., Blennow, K., White, L. R.,
and Launer, L. J. (2003). CSF Abeta
42 levels correlate with amyloid-
neuropathology in a population-
based autopsy study. Neurology 60,
652–656.
Sunderland, T., Linker, G., Mirza,
N., Putnam, K. T., Friedman, D.
L., Kimmel, L. H., Bergeson, J.,
Manetti, G. J., Zimmermann, M.,
Tang, B., Bartko, J. J., and Cohen,
R. M. (2003). Decreased beta-
amyloid1-42 and increased tau lev-
els in cerebrospinal ﬂuid of patients
with Alzheimer disease. JAMA 289,
2094–2103.
Sunderland, T., Wolozin, B., Galasko,
D., Levy, J., Dukoff, R., Bahro, M.,
Lasser, R., Motter, R., Lehtimaki, T.,
and Seubert, P. (1999). Longitudi-
nal stability of CSF tau levels in
Alzheimer patients. Biol. Psychiatry
46, 750–755.
Tapiola, T., Alafuzoff, I., Herukka, S.
K., Parkkinen, L., Hartikainen, P.,
Soininen, H., and Pirttila, T. (2009).
Cerebrospinal ﬂuid beta-amyloid 42
and tau proteins as biomarkers of
Alzheimer-type pathologic changes
in the brain. Arch. Neurol. 66,
382–389.
Teipel, S. J., Born, C., Ewers, M., Bokde,
A. L. W., Reiser, M. F., Moller, H.-J.,
andHampel,H.(2007).Multivariate
deformation based analysis of brain
atrophy to predict Alzheimer’s dis-
ease in mild cognitive impairment.
Neuroimage 28, 3–24.
Testa, C., Laakso, M. P., Sabattoli, F.,
Rossi, R., Beltramello, A., Soininen,
H., and Frisoni, G. B. (2004). A
comparisonbetweentheaccuracyof
voxel-based morphometry and hip-
pocampal volumetry in Alzheimer’s
disease. J. Magn. Reson. Imaging 19,
274–282.
Thompson, P. M., Mega, M. S., Woods,
R. P., Zoumalan, C. I., Lindschield,
C. J., Blanton, R. E., Moussai, J.,
Holmes, C. J., Cummings, J. L., and
Toga, A. W. (2001). Cortical change
in Alzheimer’s disease detected with
a disease-speciﬁc population-based
brain atlas. Cereb. Cortex 11, 1–16.
Tokuda, T., Qureshi, M. M., Ardah,
M. T., Varghese, S., Shehab, S. A.,
Kasai, T., Ishigami, N., Tamaoka,
A., Nakagawa, M., and El-Agnaf,
O. M. (2010). Detection of ele-
vated levels of alpha-synuclein
oligomers in CSF from patients with
Parkinson disease. Neurology 75,
1766–1772.
Tolboom, N., van der Flier, W. M.,
Yaqub, M., Boellaard, R., Verwey,
N. A., Blankenstein, M. A., Wind-
horst, A. D., Scheltens, P., Lam-
mertsma, A. A., and van Berckel,
B. N. (2009). Relationship of cere-
brospinal ﬂuid markers to 11C-PiB
and 18F-FDDNP binding. J. Nucl.
Med. 50, 1464–1470.
Vemuri, P., and Jack, C. R. Jr.
(2010). Role of structural MRI in
Alzheimer’s disease. Alzheimers Res
Ther 2, 23.
Vemuri, P., Wiste, H. J., Weigand, S. D.,
Knopman, D. S., Shaw, L. M., Tro-
janowski, J. Q., Aisen, P. S., Weiner,
M.,Petersen,R.C.,andJack,C.R.Jr.
(2010a). Effect of apolipoprotein E
on biomarkers of amyloid load and
neuronal pathology in Alzheimer
disease. Ann. Neurol. 67, 308–316.
Vemuri, P., Wiste, H. J., Weigand, S. D.,
Knopman, D. S., Trojanowski, J. Q.,
Shaw,L. M.,Bernstein,M. A.,Aisen,
P. S., Weiner, M., Petersen, R. C.,
and Jack, C. R. Jr. (2010b). Serial
MRI and CSF biomarkers in normal
aging, MCI, and AD. Neurology 75,
143–151.
Verhoeff,N. P.,Wilson,A. A.,Takeshita,
S., Trop, L., Hussey, D., Singh, K.,
Kung, H. F., Kung, M. P., and
Houle, S. (2004). In-vivo imag-
ing of Alzheimer disease beta-
amyloid with [11C] SB-13 PET.
Am. J. Geriatr. Psychiatry 12,
584–595.
Vigo-Pelfrey, C., Seubert, P., Barbour,
R., Blomquist, C., Lee, M., Lee, D.,
Coria, F., Chang, L., Miller, B., and
Lieberburg, I. (1995). Elevation of
microtubule-associated protein tau
in the cerebrospinal ﬂuid of patients
with Alzheimer disease. Neurology
45, 788–793.
Villemagne, V. L., Pike, K. E., Chete-
lat, G., Ellis, K. A., Mulligan, R. S.,
Bourgeat, P., Ackermann, U., Jones,
G., Szoeke, C., Salvado, O., Martins,
R.,O’Keefe,G.,Mathis,C.A.,Klunk,
W. E., Ames, D., Masters, C. L., and
Rowe, C. C. (2011). Longitudinal
assessment of Abeta and cognition
inagingandAlzheimerdisease.Ann.
Neurol. 69, 181–192.
Visser, P. J., Scheltens, P., Verhey, F. R.
J., Schmand, B., Launer, L. J., Jolles,
J., and Jonker, C. (1999). Medial
temporal lobe atrophy and mem-
ory dysfunction as predictors for
dementia in subjects with mild cog-
nitive impairment. J. Neurol. 246,
477–485.
Visser,P.J.,Verhey,F.,Knol,D.L.,Schel-
tens, P., Wahlund, L. O., Freund-
Levi, Y., Tsolaki, M., Minthon, L.,
Wallin, A. K., Hampel, H., Burger,
K., Pirttila, T., Soininen, H., Rikkert,
M. O., Verbeek, M. M., Spiru, L.,
and Blennow, K. (2009). Prevalence
and prognostic value of CSF mark-
ers of Alzheimer’s disease pathology
in patients with subjective cogni-
tive impairment or mild cognitive
impairmentintheDESCRIPAstudy:




Medial temporal lobe atrophy pre-
dicts Alzheimer’s disease in patients
with minor cognitive impairment.
J. Neurol. Neurosurg. Psychiatry 72,
491–497.
Wallin, A. K., Blennow, K., Zetterberg,
H., Londos, E., Minthon, L., and
Hansson,O.(2010).CSFbiomarkers
predict a more malignant outcome
in Alzheimer disease. Neurology 74,
1531–1537.
Whitwell, J. L., Przybelski, S. A.,
Weigand, S. D., Knopman, D.,
Boeve, B. F., Petersen, R., and Jack,
C. (2007). 3D maps from multi-
ple MRI illustrate changing atro-
phy patterns as subjects progress
from mild cognitive impairment
to Alzheimer’s disease. Brain 130,
1777–1786.
Whitwell, J. L., Shiung, M. M., Przybel-
ski, S. A., Weigand, S. D., Knopman,
D.S.,Boeve,B.F.,Petersen,R.C.,and
Jack,C.R.Jr.(2008).MRIpatternsof
atrophy associated with progression
to AD in amnestic mild cognitive
impairment.Neurology 70,512–520.
Wolk, D. A., Price, J. C., Saxton, J.,
Snitz, B., James, J. A., Lopez, O.
L., Aizenstein, H. J., Weissfeld, L.
A., Mathis, C. A., Klunk, W., and
Dekosky, S. T. (2009). Amyloid
imaging in mild cognitive impair-
ment subtypes. Ann. Neurol. 65,
557–568.




phy, and structural MR imaging for
prediction of rapid conversion to
Alzheimer disease in patients with
mild cognitive impairment: a meta-
analysis. AJNR Am. J. Neuroradiol.
30, 404–410.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received:23December2010;accepted:02
July 2011; published online: 14 July 2011.
Citation: Riverol M and López OL
(2011) Biomarkers in Alzheimer’s
disease. Front. Neur. 2:46. doi:
10.3389/fneur.2011.00046
This article was submitted to Frontiers
in Dementia, a specialty of Frontiers in
Neurology.
Copyright©2011RiverolandLópez.This
is an open-access article subject to a non-
exclusive license between the authors and
Frontiers Media SA, which permits use,
distribution and reproduction in other
forums,providedtheoriginalauthorsand
source are credited and other Frontiers
conditions are complied with.
Frontiers in Neurology | Dementia July 2011 | Volume 2 | Article 46 | 12